WO2015180685A1 - Alk激酶抑制剂及其制备方法和应用 - Google Patents
Alk激酶抑制剂及其制备方法和应用 Download PDFInfo
- Publication number
- WO2015180685A1 WO2015180685A1 PCT/CN2015/080273 CN2015080273W WO2015180685A1 WO 2015180685 A1 WO2015180685 A1 WO 2015180685A1 CN 2015080273 W CN2015080273 W CN 2015080273W WO 2015180685 A1 WO2015180685 A1 WO 2015180685A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- amino
- cycloalkyl
- mmol
- halo
- Prior art date
Links
- 0 CC(CC(*N)(*C1)C(CC*)CI)C1NC Chemical compound CC(CC(*N)(*C1)C(CC*)CI)C1NC 0.000 description 6
- JVSFQJZRHXAUGT-UHFFFAOYSA-N CC(C)(C)C(Cl)=O Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- RVKLCPONJWLSDE-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CC1c(c(C)c1)cc(OC2CC2)c1N)=O Chemical compound CC(C)(C)OC(N(CC1)CC1c(c(C)c1)cc(OC2CC2)c1N)=O RVKLCPONJWLSDE-UHFFFAOYSA-N 0.000 description 1
- KAJYWONUSHNNDZ-VOTSOKGWSA-N CC(C)CS(c1n[n](C)cc1Nc1nc(N/C=C/C(C)=C)ncc1Cl)(=O)=O Chemical compound CC(C)CS(c1n[n](C)cc1Nc1nc(N/C=C/C(C)=C)ncc1Cl)(=O)=O KAJYWONUSHNNDZ-VOTSOKGWSA-N 0.000 description 1
- BZFNWNNGQDQBGE-UHFFFAOYSA-N CC(C)CS(c1n[n](C)cc1Nc1nc(Nc(cc(C)c(C(CC2)CCC2=O)c2)c2OC2CC2)ncc1Cl)(=O)=O Chemical compound CC(C)CS(c1n[n](C)cc1Nc1nc(Nc(cc(C)c(C(CC2)CCC2=O)c2)c2OC2CC2)ncc1Cl)(=O)=O BZFNWNNGQDQBGE-UHFFFAOYSA-N 0.000 description 1
- HVWDLWYEPBIIDR-UHFFFAOYSA-N CC(C)CS(c1n[n](C)cc1Nc1nc(Nc(cc(C)c(C(CC2)CCC2[N-](C)C)c2)c2OC2CC2)ncc1Cl)(=O)=O Chemical compound CC(C)CS(c1n[n](C)cc1Nc1nc(Nc(cc(C)c(C(CC2)CCC2[N-](C)C)c2)c2OC2CC2)ncc1Cl)(=O)=O HVWDLWYEPBIIDR-UHFFFAOYSA-N 0.000 description 1
- NWMMHEIAHWNLPI-KHPPLWFESA-N CC(C)O/C(/C=C)=C(/C=C(C)C)\[N+]([O-])=O Chemical compound CC(C)O/C(/C=C)=C(/C=C(C)C)\[N+]([O-])=O NWMMHEIAHWNLPI-KHPPLWFESA-N 0.000 description 1
- SGMSDLSOLHVCBL-UHFFFAOYSA-N CC(C)Oc(cc(C(C1)CN1C(OC(C)(C)C)=O)c(C)c1)c1[N+]([O-])=O Chemical compound CC(C)Oc(cc(C(C1)CN1C(OC(C)(C)C)=O)c(C)c1)c1[N+]([O-])=O SGMSDLSOLHVCBL-UHFFFAOYSA-N 0.000 description 1
- MNUPHINLCXJKEZ-UHFFFAOYSA-N CC(C)Oc(cc(C(CC1)CCN1C(OC(C)(C)C)=O)c(C)c1)c1N Chemical compound CC(C)Oc(cc(C(CC1)CCN1C(OC(C)(C)C)=O)c(C)c1)c1N MNUPHINLCXJKEZ-UHFFFAOYSA-N 0.000 description 1
- FGDOUMVPHJHSCK-UHFFFAOYSA-N CC(C)Oc(cc(c(C)c1)-c2ccncc2)c1[N+]([O-])=O Chemical compound CC(C)Oc(cc(c(C)c1)-c2ccncc2)c1[N+]([O-])=O FGDOUMVPHJHSCK-UHFFFAOYSA-N 0.000 description 1
- BXGPNORVNAFECY-UHFFFAOYSA-N CC(C)Oc1cc(N)c(C)cc1[N+]([O-])=O Chemical compound CC(C)Oc1cc(N)c(C)cc1[N+]([O-])=O BXGPNORVNAFECY-UHFFFAOYSA-N 0.000 description 1
- PJDNVKZYEWLEGO-KOHMAYGUSA-N CC(C)S(C(/C(/Nc1nc(Nc(cc(C)c(C(CC2)CCN2C(C(C)(C)C)=O)c2)c2OC2CC2)ncc1Cl)=C\NC)=N)(=O)=O Chemical compound CC(C)S(C(/C(/Nc1nc(Nc(cc(C)c(C(CC2)CCN2C(C(C)(C)C)=O)c2)c2OC2CC2)ncc1Cl)=C\NC)=N)(=O)=O PJDNVKZYEWLEGO-KOHMAYGUSA-N 0.000 description 1
- BPHGIRALUMDCQZ-QRPNVLAJSA-N CC(C)S(C(/C(/Nc1nc(Nc(cc(C)c(C2CCNCC2)c2)c2OC2CC2)ncc1Cl)=C\NC)=N)(=O)=O Chemical compound CC(C)S(C(/C(/Nc1nc(Nc(cc(C)c(C2CCNCC2)c2)c2OC2CC2)ncc1Cl)=C\NC)=N)(=O)=O BPHGIRALUMDCQZ-QRPNVLAJSA-N 0.000 description 1
- UODMZTNWRSEWHS-UHFFFAOYSA-N CC(C)S(c1n[n](C)cc1N)(=O)=O Chemical compound CC(C)S(c1n[n](C)cc1N)(=O)=O UODMZTNWRSEWHS-UHFFFAOYSA-N 0.000 description 1
- CJGQQAMVZGVFMK-UHFFFAOYSA-N CC(C)S(c1n[n](C)cc1Nc1nc(Cl)ncc1Cl)(=O)=O Chemical compound CC(C)S(c1n[n](C)cc1Nc1nc(Cl)ncc1Cl)(=O)=O CJGQQAMVZGVFMK-UHFFFAOYSA-N 0.000 description 1
- WVNVADHGENJMSD-UHFFFAOYSA-N CC(C)S(c1n[n](C)cc1Nc1nc(Nc(cc(C)c(C(CC2)CCC2=O)c2)c2OC2CC2)ncc1Cl)(=O)=O Chemical compound CC(C)S(c1n[n](C)cc1Nc1nc(Nc(cc(C)c(C(CC2)CCC2=O)c2)c2OC2CC2)ncc1Cl)(=O)=O WVNVADHGENJMSD-UHFFFAOYSA-N 0.000 description 1
- GBAAUPMMLSBTLE-UHFFFAOYSA-N CC(C)S(c1n[n](C)cc1Nc1nc(Nc(cc(C)c(C(CC2)CCN2C(CN(C)C)=O)c2)c2OC2CC2)ncc1Cl)(=O)=O Chemical compound CC(C)S(c1n[n](C)cc1Nc1nc(Nc(cc(C)c(C(CC2)CCN2C(CN(C)C)=O)c2)c2OC2CC2)ncc1Cl)(=O)=O GBAAUPMMLSBTLE-UHFFFAOYSA-N 0.000 description 1
- ZVTCEMYLHSLGPR-UHFFFAOYSA-N CC(C)S(c1n[n](C)cc1Nc1nc(Nc(cc(C)c(C2CCNCC2)c2)c2OC2CC2)ncc1Cl)(=O)=O Chemical compound CC(C)S(c1n[n](C)cc1Nc1nc(Nc(cc(C)c(C2CCNCC2)c2)c2OC2CC2)ncc1Cl)(=O)=O ZVTCEMYLHSLGPR-UHFFFAOYSA-N 0.000 description 1
- XPUDDYPIINWILB-MXVIHJGJSA-N CC(C)S(c1n[n](C)cc1Nc1nc(Nc(cc(C)c([C@H](CC2)CC[C@@H]2NC(C)=O)c2)c2OC2CC2)ncc1Cl)(=O)=O Chemical compound CC(C)S(c1n[n](C)cc1Nc1nc(Nc(cc(C)c([C@H](CC2)CC[C@@H]2NC(C)=O)c2)c2OC2CC2)ncc1Cl)(=O)=O XPUDDYPIINWILB-MXVIHJGJSA-N 0.000 description 1
- YSFYCFFRWZQNFV-XUTJKUGGSA-N CC(C)S(c1n[n](C)cc1Nc1nc(Nc2cc(C)c([C@H](CC3)CC[C@@H]3NC(C3CC3)=O)cc2OC2CC2)ncc1Cl)(=O)=O Chemical compound CC(C)S(c1n[n](C)cc1Nc1nc(Nc2cc(C)c([C@H](CC3)CC[C@@H]3NC(C3CC3)=O)cc2OC2CC2)ncc1Cl)(=O)=O YSFYCFFRWZQNFV-XUTJKUGGSA-N 0.000 description 1
- WBJSDIKNNUHSSW-UHFFFAOYSA-N CC(C)Sc1n[n](C)cc1[N+]([O-])=O Chemical compound CC(C)Sc1n[n](C)cc1[N+]([O-])=O WBJSDIKNNUHSSW-UHFFFAOYSA-N 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N CC1(C)OB(B2OC(C)(C)C(C)(C)O2)OC1(C)C Chemical compound CC1(C)OB(B2OC(C)(C)C(C)(C)O2)OC1(C)C IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- PWEHOKFGEVTFPU-UHFFFAOYSA-N CCCC(N(C)C)OC1CC1 Chemical compound CCCC(N(C)C)OC1CC1 PWEHOKFGEVTFPU-UHFFFAOYSA-N 0.000 description 1
- FFDGPVCHZBVARC-UHFFFAOYSA-N CN(C)CC(O)=O Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 1
- SNGBAPNBMYIFIT-UHFFFAOYSA-N CN(CC1)Cc(cc2OC3CC3)c1cc2N Chemical compound CN(CC1)Cc(cc2OC3CC3)c1cc2N SNGBAPNBMYIFIT-UHFFFAOYSA-N 0.000 description 1
- TXHOTQZRVOQOHC-UHFFFAOYSA-N COCc1nccc(B(O)O)c1 Chemical compound COCc1nccc(B(O)O)c1 TXHOTQZRVOQOHC-UHFFFAOYSA-N 0.000 description 1
- ITIQMRYKXHSXKD-UHFFFAOYSA-N Cc(c(C1=CCOCC1)c1)cc([N+]([O-])=O)c1OC1CC1 Chemical compound Cc(c(C1=CCOCC1)c1)cc([N+]([O-])=O)c1OC1CC1 ITIQMRYKXHSXKD-UHFFFAOYSA-N 0.000 description 1
- GLMXDEQLHICKOR-UHFFFAOYSA-N Cc(c(C=O)c1)cc([N+]([O-])=O)c1OC1CC1 Chemical compound Cc(c(C=O)c1)cc([N+]([O-])=O)c1OC1CC1 GLMXDEQLHICKOR-UHFFFAOYSA-N 0.000 description 1
- YXVJHZWHPLOEAP-UHFFFAOYSA-N Cc(c(Cl)c1)cc([N+]([O-])=O)c1F Chemical compound Cc(c(Cl)c1)cc([N+]([O-])=O)c1F YXVJHZWHPLOEAP-UHFFFAOYSA-N 0.000 description 1
- CSARJIQZOSVYHA-UHFFFAOYSA-N Cc(ccc(F)c1)c1Cl Chemical compound Cc(ccc(F)c1)c1Cl CSARJIQZOSVYHA-UHFFFAOYSA-N 0.000 description 1
- ALGDKINLACWIRM-UHFFFAOYSA-N Cc1cc(B(O)O)cc(C)n1 Chemical compound Cc1cc(B(O)O)cc(C)n1 ALGDKINLACWIRM-UHFFFAOYSA-N 0.000 description 1
- VTRFAYHJKSKHGY-UHFFFAOYSA-N Cc1cc(Br)cc(C)n1 Chemical compound Cc1cc(Br)cc(C)n1 VTRFAYHJKSKHGY-UHFFFAOYSA-N 0.000 description 1
- SVHOGXCJBBYKOT-UHFFFAOYSA-N NC(c1n[nH]cc1[N+]([O-])=O)=O Chemical compound NC(c1n[nH]cc1[N+]([O-])=O)=O SVHOGXCJBBYKOT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- the present invention relates to the field of medicinal chemistry, and in particular to compounds which inhibit, modulate and/or modulate signal transduction of ALK kinase, their preparation, pharmaceutical compositions containing them and their use as medicaments.
- Protein kinases are enzyme components of signaling pathways that catalyze the migration of terminal phosphates from ATP to the hydroxyl groups of tyrosine, serine and/or threonine residues of proteins. Thus, compounds that inhibit protein kinase function are valuable tools for assessing the physiological consequences of protein kinase activity.
- Overexpression or inappropriate expression of mammalian normal or mutant protein kinases has been the subject of extensive research and has been demonstrated in many diseases including diabetes, angiogenesis, psoriasis, restenosis, eye disease, schizophrenia, It plays an important role in the development of rheumatoid arthritis, atherosclerosis, cardiovascular disease and cancer. Protein kinase inhibitors have particular utility in the treatment of human and animal diseases.
- Protein phosphorylation represents a process by which intracellular signals travel between molecules and molecules, ultimately leading to cellular responses. Protein phosphorylation occurs primarily on serine, threonine or tyrosine residues, and protein kinases have been classified according to their specificity for phosphorylation sites, namely serine/threonine kinases and tyrosine kinases.
- Anaplastic lymphoma kinase is a member of the receptor tyrosine kinase family, which recruits downstream protein molecules by autophosphorylation to express specific genes and regulate cell growth and metabolism.
- Anaplastic lymphoma kinase was first discovered in Anaplastic large cell lymphoma (ALCL).
- ALK Anaplastic large cell lymphoma
- the abnormal expression of ALK in some ALCL is derived from different chromosomal ectopic, and the fusion protein produced by ALK ectopic is carcinogenic. The role of genes.
- This fusion protein retains the intracellular kinase portion of ALK and fuses the N-terminal fragment of the protein to which it is fused, resulting in high expression and overactivation of intracellular ALK kinase, causing cells Malignant transformation.
- ALK can also cause excessive activation of intracellular ALK kinase through gene mutations and overexpression of various causes.
- ALK Large cell lymphoma
- IMT inflammatory myofibroblastic tumor
- DLBCL diffuse large B-cell lymphoma
- NSCLC non-small cell lung cancer
- RMC renal medullary carcinoma
- RRC renal cell carcinoma
- breast cancer colon cancer
- SOC ovarian serous carcinoma
- ESCC esophageal squamous cell carcinoma
- the present invention provides a compound as an ALK kinase inhibitor or a pharmaceutically acceptable salt thereof, wherein the compound as an ALK kinase inhibitor has a structure represented by the following formula I,
- R 1 is alkyl, haloalkyl or -OR 4 wherein R 4 is hydrogen, C 1-8 alkyl, halo C 1-8 alkyl, C 3-8 cycloalkyl, halo C 3-8 ring Alkyl, C 1-8 alkyl-C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-8 alkyl, substituted or unsubstituted heterocyclic group, or substituted or unsubstituted heterocyclic ring Base-C 1-8 alkyl;
- R 2 is alkyl, cycloalkyl, heterocycloalkyl or heterocycloalkenyl, which may be optionally substituted by one to three substituents independently selected from the group consisting of oxy, C 1-8 alkane Base, halo C 1-8 alkyl, C 1-8 alkoxy, halo C 1-8 alkoxy, C 3-8 cycloalkyl, halo C 3-8 cycloalkyl, C 3- 8- cycloalkoxy, halo C 3-8 cycloalkoxy, C 1-8 alkoxy-C 1-8 alkyl, hydroxy-C 1-8 alkyl, amino-C 1-8 alkyl, Carboxyl-C 1-8 alkyl, C 1-8 alkyl-amino-C 1-8 alkyl, halogen, hydroxy, cyano, cyano-C 1-8 alkyl, amino, C 1-8 alkyl -amino, bis(C 1-8 alkyl)-amino, C 3-8 cycl
- R 3 is -SO 2 R 7 , -SO 2 NR 7 R 8 , -CN, -CONR 7 R 8 , or -COR 7 , wherein R 7 and R 8 are each independently hydrogen, alkyl or cycloalkyl;
- X is a chemical bond, O, S, CO, NR 9 , SO 2 or S(O), wherein R 9 is hydrogen, C 1-8 alkyl, halogenated C 1-8 alkyl, C 3-8 cycloalkyl , halogenated C 3-8 cycloalkyl, C 1-8 alkyl-CO or 4-6 membered heterocyclic group.
- Z 1 is N or CR 10 , wherein R 10 is hydrogen, halogen, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxy, haloalkoxy or cyano;
- Z 2 is CR 11 or N, wherein R 11 is hydrogen, C 1-8 alkyl, halo C 1-8 alkyl, C 3-8 cycloalkyl, halo C 3-8 cycloalkyl, C 1 -8 alkoxy, halo C 1-8 alkoxy, C 3-8 cycloalkoxy, halo C 3-8 cycloalkoxy, halogen, amino, C 1-8 alkyl-amino, (C 1-8 alkyl)-amino or cyano, wherein R 11 optionally forms a ring together with R 2 and the carbon atom to which they are attached, said ring optionally being independently selected from 1 to 3 Substituted from the following groups of substituents: oxy, C 1-8 alkyl, halo C 1-8 alkyl, C 1-8 alkoxy, halo C 1-8 alkoxy, C 3-8 Cycloalkyl, halo C 3-8 cycloalkyl, C 3-8 cycloalkoxy, hal
- Z 3 , Z 4 and Z 5 are selected from the group consisting of:
- Z 3 is N, Z 4 is NR 14 , and Z 5 is CH or N;
- Z 3 is N, Z 4 is CR 14 , and Z 5 is N, O or S;
- Z 3 is O or S, Z 4 is NR 14 , and Z 5 is CH;
- Z 3 is O or S, Z 4 is CR 14 , and Z 5 is N;
- Z 3 is C, Z 4 is NR 14 , and Z 5 is O or S;
- R 14 is hydrogen, alkyl, haloalkyl, C 3-8 cycloalkyl, halo C 3-8 cycloalkyl or 4-6 membered heterocyclyl.
- R 1 is C 1-8 alkyl, halo C 1-8 alkyl or -OR 4, wherein R 4 is hydrogen, C 1-8 alkyl, halo C 1-8 alkyl a C 3-8 cycloalkyl group, a halogenated C 3-8 cycloalkyl group, a C 1-8 alkyl-C 3-8 cycloalkyl group, a C 3-8 cycloalkyl-C 1-8 alkyl group, A substituted or unsubstituted 4-7 membered heterocyclic group or a substituted or unsubstituted 4-7 membered heterocyclyl-C 1-8 alkyl group.
- the substituted or unsubstituted 4-7 membered heterocyclyl is substituted or unsubstituted 4-7 membered heterocyclyl containing 1 or 2 heteroatoms selected from N, O and S. .
- the substituted or unsubstituted 4-7 membered heterocyclyl-C 1-8 alkyl group is substituted or unsubstituted containing 1 or 2 heteroatoms selected from N, O, and S. 4-7 membered heterocyclyl-C 1-8 alkyl.
- R 1 is C 1-8 alkyl or -OR 4 , wherein R 4 is C 1-5 alkyl, halo C 1-5 alkyl, C 3-7 cycloalkyl, halo Generation C 3-7 cycloalkyl or C 3-7 cycloalkyl-methyl.
- R 4 is methyl, ethyl, n-propyl, isopropyl, cyclopropyl, trifluoromethyl, cyclobutyl or cyclopropylmethyl.
- R 2 is C 1-8 alkyl, C 3-8 cycloalkyl, 4-7 membered heterocycloalkyl or 4-7 membered heterocycloalkenyl, which may be optionally 1 - 3 substituents independently selected from the group consisting of oxy, C 1-8 alkyl, halo C 1-8 alkyl, C 1-8 alkoxy, halo C 1-8 alkoxy Base, C 3-8 cycloalkyl, halogenated C 3-8 cycloalkyl, C 3-8 cycloalkoxy, halogenated C 3-8 cycloalkoxy, C 1-8 alkoxy-C 1 -8 alkyl, hydroxy-C 1-8 alkyl, amino-C 1-8 alkyl, carboxy-C 1-8 alkyl, C 1-8 alkyl-amino-C 1-8 alkyl, halogen, Hydroxy, cyano, cyano-C 1-8 alkyl, amino, C 1-8 alkyl-amino, bis(
- R 2 is C 1-8 alkyl, C 3-8 cycloalkyl, 4-7 membered heterocycloalkyl containing 1 or 2 heteroatoms selected from N, O, and S or a 4-7 membered heterocycloalkenyl group comprising 1 or 2 heteroatoms selected from N, O and S, which may be optionally substituted with from 1 to 3 substituents independently selected from the group consisting of oxy, C 1-8 alkyl, halo C 1-8 alkyl, C 1-8 alkoxy, halo C 1-8 alkoxy, C 3-8 cycloalkyl, halo C 3-8 naphthenic Base, C 3-8 cycloalkoxy, halogenated C 3-8 cycloalkoxy, C 1-8 alkoxy-C 1-8 alkyl, hydroxy-C 1-8 alkyl, amino-C 1 -8 alkyl, carboxy-C 1-8 alkyl, C 1-8 alkyl-amino-C 1-8 alkyl, halogen
- R 2 is cyclohexane, piperidinyl, pyrrolidinyl, azetidinyl, tetrahydropyranyl, morphinolinyl or 3-4 entridinyl, which are optionally 1 - 3 substituents independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, cyclopropyl, cyclo Butyl, butyl butyl, methoxy, methoxymethyl, methoxyethyl, fluoro, chloro, cyano, amino, cyclopropylamino, (isopropyl, methyl)-amino, formyl, acetyl a group, a trifluoroacetyl group, a cyclopropyl formyl group, -COR 5 , -
- R 3 is -SO 2 R 7, -SO 2 NR 7 R 8, -CN, -CONR 7 R 8, or -COR 7, wherein R 7 and R 8 independently of one another hydrogen, C 1-8 alkyl or C 3-8 cycloalkyl.
- R 3 is —SO 2 R 7 , wherein R 7 is hydrogen, C 1-8 alkyl or C 3-8 cycloalkyl. In certain embodiments, R 7 is isopropyl, sec-butyl or isobutyl.
- X is a chemical bond or CO.
- Z 1 is CR 10 , wherein R 10 is hydrogen, halogen, C 1-8 alkyl, halo C 1-8 alkyl, C 3-8 cycloalkyl, halo C 3 8 -cycloalkyl, C 1-8 alkoxy, halo C 1-8 alkoxy or cyano; preferably, R 10 is halogen; more preferably, R 10 is chloro.
- Z 2 is CR 11 , wherein R 11 is hydrogen, C 1-8 alkyl, halo or cyano, wherein R 11 is optionally formed with R 2 and the carbon atom to which they are attached Rings, which may be optionally substituted with from 1 to 3 substituents independently selected from the group consisting of oxy, C 1-8 alkyl, halo C 1-8 alkyl, C 1-8 alkoxy a halogenated C 1-8 alkoxy group, a C 3-8 cycloalkyl group, a halogenated C 3-8 cycloalkyl group, a C 3-8 cycloalkoxy group, a halogenated C 3-8 cycloalkoxy group, C 1-8 alkoxy-C 1-8 alkyl, hydroxy-C 1-8 alkyl, amino-C 1-8 alkyl, carboxy-C 1-8 alkyl, C 1-8 alkyl-amino -C 1-8 alkyl, halogen, hydroxy, cyano,
- R 11 and R 2 together with the carbon atom to which they are attached form a ring.
- Z 2 is CR 11 , wherein R 11 is hydrogen, C 1-8 alkyl, halo or cyano. In certain embodiments, R 11 is hydrogen, methyl, fluoro, chloro or cyano.
- Z 3 , Z 4 and Z 5 are selected from the group consisting of
- Z 3 is N
- Z 4 is NR 14
- Z 5 is CH or N.
- Z 3 is N
- Z 4 is CR 14
- Z 5 is N, O or S
- Z 3 is O or S
- Z 4 is NR 14
- Z 5 is CH.
- Z 3 is O or S
- Z 4 is CR 14
- Z 5 is N
- Z 3 is C
- Z 4 is NR 14
- Z 5 is O or S.
- R 14 is hydrogen, C 1-8 alkyl, C 3-8 cycloalkyl, halogenated C 3-8 cycloalkyl, 4-6 comprising 1 or 2 heteroatoms selected from N, O and S A heterocyclic group or a halogenated 4-6 membered heterocyclic group containing 1 or 2 hetero atoms selected from N, O and S.
- Z 3 is N
- Z 4 is NR 14
- Z 5 is CH
- R 14 is hydrogen, C 1-8 alkyl, C 3-8 cycloalkyl, halo C 3-8 a cycloalkyl group, a 4-6 membered heterocyclic group containing 1 or 2 hetero atoms selected from N, O and S or a halogenated 4-6 member containing 1 or 2 hetero atoms selected from N, O and S Heterocyclic group.
- R 14 is C 1-8 alkyl or C 3-8 cycloalkyl.
- R 14 is methyl or cyclopropyl.
- Z 3 is N
- Z 4 is CR 14
- Z 5 is S, wherein R 14 is C 1-8 alkyl or C 3-8 cycloalkyl; preferably, R 14 is methyl Or cyclopropyl.
- the compound has the following structural formula:
- R 15 and R 16 are, independently of each other, C 1-8 alkyl, C 3-8 cycloalkyl, C 1-8 alkoxy-C 1-8 alkyl, hydroxy-C 1-8 alkyl, amino -C 1-8 alkyl, C 1-8 alkyl-CO, C 1-8 alkyl-amino-C 1-8 alkyl or di(C 1-8 alkyl)-amino-C 1-8 alkane base.
- R 1 , R 3 , Z 1 , Z 2 , Z 3 , Z 4 and Z 5 are as defined above.
- the compound has the following structural formula:
- R 17 and R 18 are each independently C 1-8 alkyl, C 3-8 cycloalkyl, C 1-8 alkoxy-C 1-8 alkyl, hydroxy-C 1-8 alkyl, amino -C 1-8 alkyl, C 1-8 alkyl-CO, C 1-8 alkyl-amino-C 1-8 alkyl or di(C 1-8 alkyl)-amino-C 1-8 alkane base.
- R 1 , R 3 , Z 1 , Z 3 , Z 4 and Z 5 are as defined above.
- the compound of formula I is selected from the group consisting of:
- the invention provides a method of preparing a compound of formula I above, the method comprising the steps of:
- R 1 , R 2 , R 3 , X, Z 1 , Z 2 , Z 3 , Z 4 and Z 5 are as defined above, and R is a precursor of R 2 , generally R 2 with a protecting group, the protecting group For example, it may be a tert-butyloxycarbonyl group, a trifluoroacetyl group or the like.
- the method of preparing a compound of Formula I comprises the steps of:
- R 1 , R 2 , R 3 , X, Z 1 , Z 2 , Z 3 , Z 4 and Z 5 are as defined above.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising the above compound or a pharmaceutically acceptable salt thereof, the pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient.
- the pharmaceutical composition is a tablet, a capsule, a pill, a granule, a powder, a suppository, an injection, a solution, a suspension, a plaster, a patch, a lotion, a drop, a liniment Or a spray.
- the present invention provides the use of the above compound or a pharmaceutically acceptable salt thereof and/or a pharmaceutical composition for the preparation of an antitumor drug.
- the anti-tumor drug is applied to the following conditions: melanoma, neuroblastoma, glioblastoma, rhabdomyosarcoma, astrocytoma, Ewing's sarcoma, retinoblastoma, inter Denaturing large cell lymphoma, inflammatory myofibroblastoma, diffuse large B-cell lymphoma, non-small cell lung cancer, renal medullary carcinoma, renal cell carcinoma, breast cancer, colon cancer, ovarian serous carcinoma and esophageal squamous Cellular cancer.
- the invention provides a method of treating a tumor in a subject comprising administering to the subject a therapeutically effective amount of a compound described above, or a pharmaceutically acceptable salt or pharmaceutical composition thereof.
- the subject is a mammal.
- the subject is a human.
- the modes of administration include oral, mucosal, sublingual, ocular, topical, parenteral, rectal, cerebral, vaginal, peritoneal, bladder, nasal administration.
- One aspect of the present invention provides a compound which is an inhibitor of ALK kinase or a pharmaceutically acceptable salt thereof, which has a structure represented by the following formula I,
- R 1 is alkyl, haloalkyl or -OR 4 wherein R 4 is hydrogen, C 1-8 alkyl, halo C 1-8 alkyl, C 3-8 cycloalkyl, halo C 3-8 ring Alkyl, C 1-8 alkyl-C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-8 alkyl, substituted or unsubstituted heterocyclic group, or substituted or unsubstituted heterocyclic ring Base-C 1-8 alkyl;
- R 2 is alkyl, cycloalkyl, heterocycloalkyl or heterocycloalkenyl, which may be optionally substituted by one to three substituents independently selected from the group consisting of oxy, C 1-8 alkane Base, halo C 1-8 alkyl, C 1-8 alkoxy, halo C 1-8 alkoxy, C 3-8 cycloalkyl, halo C 3-8 cycloalkyl, C 3- 8- cycloalkoxy, halo C 3-8 cycloalkoxy, C 1-8 alkoxy-C 1-8 alkyl, hydroxy-C 1-8 alkyl, amino-C 1-8 alkyl, Carboxyl-C 1-8 alkyl, C 1-8 alkyl-amino-C 1-8 alkyl, halogen, hydroxy, cyano, cyano-C 1-8 alkyl, amino, C 1-8 alkyl -amino, bis(C 1-8 alkyl)-amino, C 3-8 cycl
- R 3 is -SO 2 R 7 , -SO 2 NR 7 R 8 , -CN, -CONR 7 R 8 , or -COR 7 , wherein R 7 and R 8 are each independently hydrogen, alkyl or cycloalkyl;
- X is a chemical bond, O, S, CO, NR 9 , SO 2 or S(O), wherein R 9 is hydrogen, C 1-8 alkyl, halogenated C 1-8 alkyl, C 3-8 cycloalkyl , halogenated C 3-8 cycloalkyl, C 1-8 alkyl-CO or 4-6 membered heterocyclic group.
- Z 1 is N or CR 10 , wherein R 10 is hydrogen, halogen, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxy, haloalkoxy or cyano;
- Z 2 is CR 11 or N, wherein R 11 is hydrogen, C 1-8 alkyl, halo C 1-8 alkyl, C 3-8 cycloalkyl, halo C 3-8 cycloalkyl, C 1 -8 alkoxy, halo C 1-8 alkoxy, C 3-8 cycloalkoxy, halo C 3-8 cycloalkoxy, halogen, amino, C 1-8 alkyl-amino, (C 1-8 alkyl)-amino or cyano, wherein R 11 optionally forms a ring together with R 2 and the carbon atom to which they are attached, said ring optionally being independently selected from 1 to 3 Substituted from the following groups of substituents: oxy, C 1-8 alkyl, halo C 1-8 alkyl, C 1-8 alkoxy, halo C 1-8 alkoxy, C 3-8 Cycloalkyl, halo C 3-8 cycloalkyl, C 3-8 cycloalkoxy, hal
- Z 3 , Z 4 and Z 5 are selected from the group consisting of:
- Z 3 is N, Z 4 is NR 14 , and Z 5 is CH or N;
- Z 3 is N, Z 4 is CR 14 , and Z 5 is N, O or S;
- Z 3 is O or S, Z 4 is NR 14 , and Z 5 is CH;
- Z 3 is O or S, Z 4 is CR 14 , and Z 5 is N;
- Z 3 is C, Z 4 is NR 14 , and Z 5 is O or S;
- R 14 is hydrogen, alkyl, haloalkyl, C 3-8 cycloalkyl, halo C 3-8 cycloalkyl or 4-6 membered heterocyclyl.
- R 1 is C 1-8 alkyl.
- R 1 is a C 1-6 alkyl group. More preferably, R 1 is a C 1-4 alkyl group.
- R 1 is haloalkyl.
- R 1 is a halogenated C 1-4 alkyl group.
- R 1 is —OR 4 , wherein R 4 is hydrogen, C 1-8 alkyl, halo C 1-8 alkyl, C 3-8 cycloalkyl, halo C 3-8 Cycloalkyl, C 1-8 alkyl-C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-8 alkyl, substituted or unsubstituted 4-7 membered heterocyclic group or substituted or unsubstituted Substituted 4-7 membered heterocyclyl-C 1-8 alkyl.
- R 4 is C 1-6 alkyl, halo C 1-6 alkyl, C 3-6 cycloalkyl, halo C 3-6 cycloalkyl, C 1-6 alkyl-C 3- 6 cycloalkyl, C 3-6 cycloalkyl-C 1-6 alkyl, substituted or unsubstituted 4-6 membered heterocyclic group or substituted or unsubstituted 4-6 membered heterocyclic group -C 1-6 alkyl.
- R 4 is C 1-4 alkyl, halo C 1-4 alkyl, C 3-4 cycloalkyl, halo C 3-4 cycloalkyl, C 1-4 alkyl-C 3 -4 cycloalkyl, C 3-4 cycloalkyl-C 1-4 alkyl.
- the heterocyclyl is a heterocyclyl containing 1 or 2 heteroatoms selected from the group consisting of N, O, and S.
- R 4 is C 1-5 alkyl, halo C 1-5 alkyl, C 3-7 cycloalkyl, halo C 3-7 cycloalkyl or C 3-7 naphthenic Base-methyl.
- R 4 is methyl, ethyl, n-propyl, isopropyl, cyclopropyl, trifluoromethyl, cyclobutyl or cyclopropylmethyl.
- R 2 is C 1-8 alkyl, C 3-8 cycloalkyl, 4-7 membered heterocycloalkyl or 4-7 membered heterocycloalkenyl, which may be optionally 1 - 3 substituents independently selected from the group consisting of oxy, C 1-8 alkyl, halo C 1-8 alkyl, C 1-8 alkoxy, halo C 1-8 alkoxy Base, C 3-8 cycloalkyl, halogenated C 3-8 cycloalkyl, C 3-8 cycloalkoxy, halogenated C 3-8 cycloalkoxy, C 1-8 alkoxy-C 1 -8 alkyl, hydroxy-C 1-8 alkyl, amino-C 1-8 alkyl, carboxy-C 1-8 alkyl, C 1-8 alkyl-amino-C 1-8 alkyl, halogen, Hydroxy, cyano, cyano-C 1-8 alkyl, amino, C 1-8 alkyl-amino, bis(
- R 2 is C 1-8 alkyl, C 3-8 cycloalkyl, 4-7 membered heterocycloalkyl containing 1 or 2 heteroatoms selected from N, O, and S or a 4-7 membered heterocycloalkenyl group comprising 1 or 2 heteroatoms selected from N, O and S, which may be optionally substituted with from 1 to 3 substituents independently selected from the group consisting of oxy, C 1-8 alkyl, halo C 1-8 alkyl, C 1-8 alkoxy, halo C 1-8 alkoxy, C 3-8 cycloalkyl, halo C 3-8 naphthenic Base, C 3-8 cycloalkoxy, halogenated C 3-8 cycloalkoxy, C 1-8 alkoxy-C 1-8 alkyl, hydroxy-C 1-8 alkyl, amino-C 1 -8 alkyl, carboxy-C 1-8 alkyl, C 1-8 alkyl-amino-C 1-8 alkyl, halogen
- R 2 is C 1-6 alkyl, C 3-6 cycloalkyl, 4-6 membered heterocycloalkyl containing 1 or 2 heteroatoms selected from N, O, and S or a 4-6 membered heterocycloalkenyl group comprising 1 or 2 heteroatoms selected from N, O and S, which may be optionally substituted with from 1 to 3 substituents independently selected from the group consisting of oxy, C 1-6 alkyl, halo C 1-6 alkyl, C 1-6 alkoxy, halo C 1-6 alkoxy, C 3-6 cycloalkyl, halo C 3-6 naphthenic Base, C 3-6 cycloalkoxy, halo C 3-6 cycloalkoxy, C 1-6 alkoxy-C 1-6 alkyl, hydroxy-C 1-6 alkyl, amino-C 1 -6 alkyl, carboxy-C 1-6 alkyl, C 1-6 alkyl-amino-C 1-6 alkyl, halogen,
- R 2 is C 1-6 alkyl, C 3-6 cycloalkyl, 4-6 membered heterocycloalkyl containing 1 or 2 heteroatoms selected from N, O, and S or a 4-6 membered heterocycloalkenyl group comprising 1 or 2 heteroatoms selected from N, O and S, which may be optionally substituted with from 1 to 3 substituents independently selected from the group consisting of oxy, C 1-5 alkyl, halo C 1-5 alkyl, C 1-5 alkoxy, halo C 1-5 alkoxy, C 3-5 cycloalkyl, halo C 3-5 naphthenic Base, C 3-5 cycloalkoxy, halo C 3-5 cycloalkoxy, C 1-5 alkoxy-C 1-5 alkyl, hydroxy-C 1-5 alkyl, amino-C 1 -5 alkyl, carboxy-C 1-5 alkyl, C 1-5 alkyl-amino-C 1-5 alkyl, halogen,
- R 2 is C 1-6 alkyl, C 3-6 cycloalkyl, 4-6 membered heterocycloalkyl containing 1 or 2 heteroatoms selected from N, O, and S or a 4-6 membered heterocycloalkenyl group comprising 1 or 2 heteroatoms selected from N, O and S, which may be optionally substituted with from 1 to 3 substituents independently selected from the group consisting of oxy, C 1-4 alkyl, halo C 1-4 alkyl, C 1-4 alkoxy, halo C 1-4 alkoxy, C 3-4 cycloalkyl, halo C 3-4 naphthenic Base, C 3-4 cycloalkoxy, halo C 3-4 cycloalkoxy, C 1-4 alkoxy-C 1-4 alkyl, hydroxy-C 1-4 alkyl, amino-C 1 -4 alkyl, carboxy-C 1-6 alkyl, C 1-4 alkyl-amino-C 1-4 alkyl, halogen,
- R 2 is cyclohexane, piperidinyl, pyrrolidinyl, azetidinyl, tetrahydropyranyl, morphinolinyl or 3-4 entridinyl, which are optionally 1 - 3 substituents independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, cyclopropyl, cyclo Butyl, butyl butyl, methoxy, methoxymethyl, methoxyethyl, fluoro, chloro, cyano, amino, cyclopropylamino, (isopropyl, methyl)-amino, formyl, acetyl a group, a trifluoroacetyl group, a cyclopropyl formyl group, -COR 5 , -
- R 3 is -SO 2 R 7, -SO 2 NR 7 R 8, -CN, -CONR 7 R 8, or -COR 7, wherein R 7 and R 8 independently of one another hydrogen, C 1-8 alkyl or C 3-8 cycloalkyl.
- R 7 and R 8 are each independently hydrogen, C 1-6 alkyl or C 3-6 cycloalkyl. More preferably, R 7 and R 8 are each independently hydrogen, C 1-5 alkyl or C 3-5 cycloalkyl. More preferably, R 7 and R 8 are each independently hydrogen, C 1-4 alkyl or C 3-4 cycloalkyl. More preferably, R 7 and R 8 are each independently hydrogen, C 1-3 alkyl.
- R 3 is —SO 2 R 7 , wherein R 7 is hydrogen, C 1-8 alkyl or C 3-8 cycloalkyl.
- R 7 is hydrogen, C 1-6 alkyl or C 3-6 cycloalkyl. More preferably, R 7 is hydrogen, C 1-5 alkyl or C 3-5 cycloalkyl. More preferably, R 7 is hydrogen, C 1-4 alkyl or C 3-4 cycloalkyl. In certain embodiments, R 7 is isopropyl, sec-butyl or isobutyl.
- X is a chemical bond or CO.
- Z 1 is CR 10 , wherein R 10 is hydrogen, halogen, C 1-8 alkyl, halo C 1-8 alkyl, C 3-8 cycloalkyl, halo C 3 8 -cycloalkyl, C 1-8 alkoxy, halo C 1-8 alkoxy or cyano; preferably, R 10 is halogen; more preferably, R 10 is chloro.
- Z 2 is CR 11 , wherein R 11 is hydrogen, C 1-8 alkyl, halo or cyano, wherein R 11 is optionally formed with R 2 and the carbon atom to which they are attached Rings, which may be optionally substituted with from 1 to 3 substituents independently selected from the group consisting of oxy, C 1-8 alkyl, halo C 1-8 alkyl, C 1-8 alkoxy a halogenated C 1-8 alkoxy group, a C 3-8 cycloalkyl group, a halogenated C 3-8 cycloalkyl group, a C 3-8 cycloalkoxy group, a halogenated C 3-8 cycloalkoxy group, C 1-8 alkoxy-C 1-8 alkyl, hydroxy-C 1-8 alkyl, amino-C 1-8 alkyl, carboxy-C 1-8 alkyl, C 1-8 alkyl-amino -C 1-8 alkyl, halogen, hydroxy, cyano,
- Z 2 is CR 11 , wherein R 11 is hydrogen, C 1-6 alkyl, halo or cyano, wherein R 11 is optionally formed together with R 2 and the carbon atom to which they are attached a ring, which ring may be optionally substituted with from 1 to 3 substituents independently selected from the group consisting of oxy, C 1-6 alkyl, halo C 1-6 alkyl, C 1-6 alkoxy Base, halo C 1-6 alkoxy, C 3-6 cycloalkyl, halo C 3-6 cycloalkyl, C 3-6 cycloalkoxy, halo C 3-6 cycloalkoxy, C 1-6 alkoxy-C 1-6 alkyl, hydroxy-C 1-6 alkyl, amino-C 1-6 alkyl, carboxy-C 1-6 alkyl, C 1-6 alkyl-amino -C 1-6 alkyl, halogen, hydroxy, cyano, cyano-C 1-6 alkyl,
- Z 2 is CR 11 , wherein R 11 is hydrogen, C 1-6 alkyl, halo or cyano, wherein R 11 is optionally formed together with R 2 and the carbon atom to which they are attached a ring, which may be optionally substituted with from 1 to 3 substituents independently selected from the group consisting of oxy, C 1-4 alkyl, halo C 1-4 alkyl, C 1-4 alkoxy , halo C 1-4 alkoxy, C 3-5 cycloalkyl, halo C 3-5 cycloalkyl, C 3-5 cycloalkoxy, halo C 3-5 cycloalkoxy, C 1-4 alkoxy-C 1-4 alkyl, hydroxy-C 1-4 alkyl, amino-C 1-4 alkyl, carboxy-C 1-4 alkyl, C 1-4 alkyl-amino -C 1-4 alkyl, halogen, hydroxy, cyano, cyano-C 1-6 alkyl, amino,
- Z 2 is CR 11 , wherein R 11 is hydrogen, C 1-8 alkyl, halo or cyano. In certain embodiments, R 11 is hydrogen, methyl, fluoro, chloro or cyano.
- Z 3 , Z 4 and Z 5 are selected from the group consisting of
- Z 3 is N
- Z 4 is NR 14
- Z 5 is CH or N.
- Z 3 is N
- Z 4 is CR 14
- Z 5 is N, O or S
- Z 3 is O or S
- Z 4 is NR 14
- Z 5 is CH.
- Z 3 is O or S
- Z 4 is CR 14
- Z 5 is N
- Z 3 is C
- Z 4 is NR 14
- Z 5 is O or S.
- R 14 is hydrogen, C 1-8 alkyl, C 3-8 cycloalkyl, halogenated C 3-8 cycloalkyl, 4-6 comprising 1 or 2 heteroatoms selected from N, O and S A heterocyclic group or a halogenated 4-6 membered heterocyclic group containing 1 or 2 hetero atoms selected from N, O and S.
- R 14 is C 1-6 alkyl, C 3-6 cycloalkyl, halo C 3-6 cycloalkyl, 4-5 comprising 1 or 2 heteroatoms selected from N, O and S A heterocyclic group or a halogenated 4-5 membered heterocyclic group containing 1 or 2 hetero atoms selected from N, O and S. More preferably, R 14 is C 1-4 alkyl, C 3-4 cycloalkyl, halo C 3-4 cycloalkyl.
- Z 3 is N
- Z 4 is NR 14
- Z 5 is CH
- R 14 is hydrogen, C 1-8 alkyl, C 3-8 cycloalkyl, halo C 3-8 a cycloalkyl group, a 4-6 membered heterocyclic group containing 1 or 2 hetero atoms selected from N, O and S or a halogenated 4-6 member containing 1 or 2 hetero atoms selected from N, O and S Heterocyclic group.
- R 14 is C 1-6 alkyl, C 3-6 cycloalkyl, halo C 3-6 cycloalkyl, 4-5 comprising 1 or 2 heteroatoms selected from N, O and S A heterocyclic group or a halogenated 4-5 membered heterocyclic group containing 1 or 2 hetero atoms selected from N, O and S. More preferably, R 14 is C 1-4 alkyl, C 3-4 cycloalkyl, or halogenated C 3-4 cycloalkyl. In certain embodiments, R 14 is C 1-8 alkyl or C 3-8 cycloalkyl. In certain embodiments, R 14 is methyl or cyclopropyl.
- the compound has the following structural formula:
- R 15 and R 16 are, independently of each other, C 1-8 alkyl, C 3-8 cycloalkyl, C 1-8 alkoxy-C 1-8 alkyl, hydroxy-C 1-8 alkyl, amino -C 1-8 alkyl, C 1-8 alkyl-CO, C 1-8 alkyl-amino-C 1-8 alkyl or di(C 1-8 alkyl)-amino-C 1-8 alkane base.
- the compound has the structural formula:
- R 17 and R 18 are each independently C 1-8 alkyl, C 3-8 cycloalkyl, C 1-8 alkoxy-C 1-8 alkyl, hydroxy-C 1-8 alkyl, amino -C 1-8 alkyl, C 1-8 alkyl-CO, C 1-8 alkyl-amino-C 1-8 alkyl or di(C 1-8 alkyl)-amino-C 1-8 alkane base.
- the compound of formula I of the invention is selected from the group consisting of:
- the minimum and maximum values of the carbon atom content in the hydrocarbon group are represented by a prefix, for example, the prefix (C ab ) alkyl represents any alkyl group having from “a" to "b” carbon atoms.
- (C 1-6 )alkyl means an alkyl group containing from one to six carbon atoms.
- the alkyl group is branched or linear.
- the atoms described in the compounds of the present application include their isotopes, for example, the hydrogen may be deuterium or tritium.
- Alkyl means a straight or branched, monovalent, saturated aliphatic chain including, but not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec. Butyl, tert-butyl, pentyl, isopentyl, hexyl and the like.
- a C 1-8 alkyl group is preferred. More preferably, it is a C 1-6 alkyl group. More preferably, it is a C 1-4 alkyl group.
- Cycloalkyl means a saturated monocyclic or polycyclic alkyl group which may be combined with other groups. Cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl. Preference is given to C 3-8 cycloalkyl. More preferred is a C 3-6 cycloalkyl group. More preferably, it is a C 3-4 cycloalkyl group.
- Alkoxy means a straight or branched, monovalent, saturated aliphatic chain bonded to an oxygen atom, including but not limited to, for example, methoxy, ethoxy, propoxy, butoxy , isobutoxy, tert-butoxy and other similar groups.
- a C 1-8 alkoxy group is preferred. More preferably, it is a C 1-6 alkoxy group. More preferably, it is a C 1-4 alkoxy group.
- Halogen means fluoro, chloro, bromo and iodo, preferably fluoro and chloro.
- Haloalkyl means an alkyl group as defined herein wherein one or more hydrogens have been replaced by the same or different halogens.
- exemplary haloalkyl groups include -CH 2 Cl, -CH 2 CF 3 , -CH 2 CCl 3 , perfluoroalkyl groups (e.g., -CF 3 ), and the like.
- Heterocyclyl means a non-aromatic monocyclic group bearing a heteroatom selected from N, O, or S, the remaining ring atoms being C.
- heterocyclic moiety include, but are not limited to, piperidinyl, piperazinyl, homopiperazinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, imidazolinyl, morphinolinyl, pyridyl, pyridazine , pyrimidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, quinuclidinyl, thiadiazolidine, dihydrofuranyl, tetrahydrofuranyl, dihydropyranyl, Tetrahydropyranyl, thiomorpholinyl, thiomorpholinyl sulfoxide, thiomorpholinyl sulfone,
- Aryl means a cyclic aromatic hydrocarbon including, but not limited to, phenyl, naphthyl, anthryl, phenanthryl and the like. Phenyl is preferred.
- Heteroaryl means a monocyclic or polycyclic aromatic hydrocarbon in which one or more carbon atoms have been replaced by a heteroatom such as nitrogen, oxygen or sulfur. If a heteroaryl contains more than one heteroatom, these heteroatoms may be the same or different.
- Heteroaryl groups include, but are not limited to, furyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, thienyl, isoxazolyl, oxazolyl, oxadiazolyl, imidazolyl, pyrrolyl, pyrazole , triazolyl, tetrazolyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl, benzimidazolyl, fluorenyl, carbazolyl, isoxazolyl, benzisothiazole Base, benzoxazolyl, benzoisoxazolyl and quinolyl.
- Preferred heteroaryl groups are pyridyl, oxazolyl and triazolyl.
- One cyclic group can be bonded to another group in a variety of ways. If the bonding method is not explicitly defined, it means that all possible ways are included. For example, “pyridyl” includes 2-, 3-, or 4-pyridyl, and “thienyl” includes 2- or 3-thienyl.
- “Pharmaceutically acceptable salt” refers to a conventional acid addition or base addition salt which retains the biological effectiveness and properties of a compound of formula I which is formed from a suitable non-toxic organic or inorganic acid or an organic or inorganic base.
- the acid addition salt include those derived from inorganic acids and derived from organic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, phosphoric acid and nitric acid, said organic The acid is, for example, p-toluenesulfonic acid, salicylic acid, methanesulfonic acid, oxalic acid, succinic acid, citric acid, maleic acid, lactic acid, fumaric acid or the like.
- base addition salts include salts derived from ammonium, potassium, sodium and quaternary ammonium hydroxides, such as tetramethylammonium hydroxide.
- Chemical modification of a pharmaceutical compound (ie, a drug) into a salt is well known to pharmacists. Techniques are used to obtain improved physical and chemical stability, hygroscopicity, flowability and solubility of the compounds.
- the compounds of the present invention are low in toxicity, and in particular, the inventors have selected several compounds of the invention (e.g., end products 40, 43, 44, 46, 47, 51, 57, 60, 67, 77, 80, 82, 95) , 97, 114, 133, 146, 156, 160, 161, 166, 167, 202, 204, 205, etc.) tested the inhibitory activity of the cytochrome P450 common subfamilies (1A2, 2C9, 2C19, 2D6, 3A4), No significant inhibition was found (IC50 was greater than 10 [mu]M).
- the inventors of the present patent also selected a part of the compounds for repeated rat drug administration tests.
- the compounds of the present invention can be synthesized by the following scheme. This procedure is illustrative only and not limiting of other ways in which the compound may be prepared. In addition, the steps in the scheme are only for better explanation of the preparation method of the compound of the present invention, and the steps can be modified without departing from the scope of the invention described herein.
- the present application provides a process for the preparation of a compound of formula I, the process of which is as follows:
- R 1 , R 2 , R 3 , X, Z 1 , Z 2 , Z 3 , Z 4 and Z 5 are as defined above, and R is a precursor of R 2 , generally R 2 with a protecting group, the protecting group For example, it may be a tert-butyloxycarbonyl group, a trifluoroacetyl group or the like.
- reaction formula for the method of preparing the compound of Formula I is as follows:
- R 1 , R 2 , R 3 , X, Z 1 , Z 2 , Z 3 , Z 4 and Z 5 are as defined above.
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising the compound as an ALK kinase inhibitor or a pharmaceutically acceptable salt thereof, the pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient.
- pharmaceutically acceptable carrier refers to a pharmaceutically acceptable substance, ingredient or medium, such as a liquid or solid filler, diluent, excipient, solvent or potting material, Participating in the loading or transfer of a compound of the invention from a location, body fluid, tissue, organ (internal or external), or body part to another location, body fluid, organ (internal or external), or body part.
- the pharmaceutically acceptable carrier can be a medium, diluent, excipient or other material which is not excessively toxic or side effects and which can be used to contact animal tissues.
- Typical pharmaceutically acceptable carriers include sugars, starches, cellulosics, maltose, tragacanth, gelatin, Ringer's solution, alginic acid, physiological saline, buffers and the like.
- Each pharmaceutically acceptable carrier should be compatible with the other ingredients, for example, with the compounds provided in the present invention, without excessive toxicity, irritation, allergic reaction, immunogenicity or other problems with the biological living tissue or organ or Complications, and there is a reasonable ratio of benefits to risks.
- Some pharmaceutically acceptable carriers include: (1) sugars such as lactose, glucose and sucrose; (2) starches such as corn starch and potato starch; (3) cellulose and its derivatives such as carboxymethyl Cellulose sodium, ethyl cellulose, cellulose acetate; (4) western yellow gum powder; (5) maltose; (6) gelatin; (7) talc; (8) excipients such as cocoa butter and suppositories Wax; (9) Oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols such as propylene glycol; (11) polyols such as glycerin, sorbitol, mannitol and poly Ethylene glycol; (12) lipids such as ethyl oleate, ethyl laurate; (13) agar gum; (14) buffers such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; Steril
- compositions may include pharmaceutically acceptable excipients to mimic physiological conditions such as pH adjustment and buffering agents, toxicity modifying agents, and the like, such as sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate, and the like.
- the pharmaceutical ingredients can be formulated into any suitable dosage form such as solid dosage forms (e.g., tablets, capsules, powders, granules, etc.) and liquid dosage forms (e.g., aqueous solutions, emulsions, elixirs, syrups, and the like).
- solid dosage forms e.g., tablets, capsules, powders, granules, etc.
- liquid dosage forms e.g., aqueous solutions, emulsions, elixirs, syrups, and the like.
- the compounds or pharmaceutical compositions provided herein can be formulated into a dosage form suitable for drug delivery by administration via an injection route (eg, subcutaneous, intravenous, intramuscular, arterial, intrathecal, intracapsular, box).
- an injection route eg, subcutaneous, intravenous, intramuscular, arterial, intrathecal, intracapsular, box.
- non-injectable routes eg, oral, intestinal, Oral, nasal, nasal, mucous membrane, epidermis, plaster, dermis, eye drops, lungs, sublingual, rectal, vaginal or epidermal local administration.
- Suitable dosage forms include, but are not limited to, dosage forms for injection use such as emulsions, solutions and suspensions, and dosage forms for oral use such as tablets, capsules, pills, dragees, powders and granules, topical or transdermal absorption.
- Dosage forms such as sprays, ointments, pastes, creams, lotions, gels, solutions, drug patches and inhalants, vaginal or rectal administration such as suppositories.
- These dosage forms can be prepared according to the compound and suitable excipients under suitable conditions, the preparation methods and processes are well known, such as by Remington: in The Science and Practice of Pharmacy (Gennaro ed. 20th edition, Williams & Wilkins PA, USA) (2000). .
- the present application provides a pharmaceutical composition comprising the above compound or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
- the pharmaceutical composition is a tablet, a capsule, a pill, a granule, a powder, a suppository, an injection, a solution, a suspension, a paste, a patch, a lotion, a drop, a liniment, a spray Agent.
- the present invention also provides the use of the above compound or a pharmaceutically acceptable salt thereof and/or a pharmaceutical composition for the preparation of a medicament and for the treatment of a disease.
- the invention provides the use of a compound as described above, or a pharmaceutically acceptable salt thereof and/or a pharmaceutical composition, for the manufacture of a medicament for the treatment of an antitumor.
- the present application provides the use of a compound as described above, or a pharmaceutically acceptable salt thereof and/or a pharmaceutical composition, for the manufacture of an anti-tumor drug.
- the anti-tumor drug is applied to the following conditions: melanoma, neuroblastoma, glioblastoma, rhabdomyosarcoma, astrocytoma, Ewing's sarcoma, retinoblastoma, inter Denaturing large cell lymphoma, inflammatory myofibroblastoma, diffuse large B-cell lymphoma, non-small cell lung cancer, renal medullary carcinoma, renal cell carcinoma, breast cancer, colon cancer, ovarian serous carcinoma and esophageal squamous Cellular cancer.
- the present application provides a method of treating a tumor in a subject comprising administering to the subject a therapeutically effective amount of a compound described above, or a pharmaceutically acceptable salt or pharmaceutical composition thereof.
- the subject is a mammal.
- the subject is a human.
- the modes of administration include oral, mucosal, sublingual, ocular, topical, parenteral, rectal, cerebral, vaginal, peritoneal, bladder, nasal administration.
- the compound of the present invention or a pharmaceutically acceptable salt or pharmaceutical composition thereof can be introduced into a living body by any suitable route, for example, by oral administration, intravenous injection, intranasal, external use, intramuscular injection, intradermal injection, transdermal administration or subcutaneous route. .
- the compounds of the invention, or pharmaceutically acceptable salts or pharmaceutical compositions thereof are administered by oral, mucosal, sublingual, ocular, topical, parenteral, rectal, cerebral, vaginal, peritoneal, Bladder, nasal administration.
- the compounds of the present invention can be administered concurrently with the second active agent, such that a synergistic or even synergistic effect can be achieved in the organism.
- the compounds of the present invention may be administered in combination with a second active substance in a single pharmaceutical composition, or sequentially in separate compositions.
- Second active substances which can be administered simultaneously with the compounds of the invention for the treatment of cancer include, but are not limited to, fluorouracil, doxorubicin, daunorubicin, tamoxifen, leuprolide, goserelin, fluoro Hemet, nilutamide, finasteride, dexamethasone, aminoglutethimide, ampicillin, anastrozole, asparaginase, BCG, bicalutamide, bleomycin, clinical, Busulfan, camptothecin, capecitabine, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, colchicine, cyclophosphamide, drug, cyproterone, a Cytosine, dacarbazine, actinomycin d, gentamicin, diethestrol, diethylstilbestrol, docetaxel, doxorubicin, doxorubicin, epirubici
- the compounds provided herein, or pharmaceutically acceptable salts thereof can be used in conjunction with non-chemical methods for cancer treatment. In certain embodiments, the compounds provided herein, or pharmaceutically acceptable salts thereof, can be administered concurrently with radiation therapy. In certain embodiments, the compounds provided herein can be used in combination with surgery, tumor heat therapy, ultrasound focus therapy, cryotherapy, or several of the above.
- the compounds provided herein, or pharmaceutically acceptable salts thereof can be used concurrently with a steroid.
- Suitable steroids include, but are not limited to, angiosin, beclomethasone, betamethasone, budesonide, prednisone, clobetasol, corticosterone, cortisone, and hydroxyprednisolone.
- the compounds provided herein can be used concurrently with an immunotherapeutic agent.
- immunotherapeutic agents include: tumor cell multidrug resistance reversal agents (such as verapamil), rapamycin, mycophenolate mofetil, thalidomide, cyclophosphamide, cyclosporine, and Cloning of antibodies.
- the first step cyclopropanol
- the third step 4-bromo-5-methyl-2-(trifluoromethoxy)aniline
- the third step 4-bromo-2-isopropyl-5-methylaniline
- reaction mixture was stirred at 65 ° C for 5 minutes and then cooled to room temperature and stirred for 30 minutes.
- the reaction solution was filtered to remove the insoluble material to give the title compound, N,N-dimethylformamide, and used directly for the next step.
- the third step 1-tert-butoxycarbonyl-3-(4-amino-5-isopropyloxy-2-methylphenyl)azetidine
- Second step 4-(5-cyclopropoxy-2-methyl-4-nitrophenyl)-1-(2-methoxyethyl)-1,2,3,6-tetrahydropyridine
- the third step 2-cyclopropoxy-4-(1-(2-methoxyethyl)piperidin-4-yl)-5-methylaniline
- Second step 2-(4-(5-cyclopropoxy-2-methyl-4-nitrophenyl)-5,6-dihydropyridine-1(2H)-yl)-2-methyl -1-propanol
- the third step 4-(5-cyclopropoxy-2-methyl-4-nitrophenyl)-1-(1-methoxy-2-methylpropan-2-yl)-1,2, 3,6-tetrahydropyridine
- the fourth step 2-cyclopropoxy-4-(1-(1-methoxy-2-methylpropan-2-yl)-piperidin-4-yl)-5-methylaniline
- Second step 1 (2H)-tert-butoxycarbonyl-4-(5-(cyclopropylmethoxy)-2-methyl-4-nitrophenyl)-5,6-dihydropyridine
- the third step 2-methoxymethylpyridine-4-boronic acid
- Second step 4-(5-isopropoxy-2-methyl-4-nitrophenyl)-1-methyl-pyridinium iodide
- reaction mixture was re-cooled to 0 ° C, then 4N aqueous sodium hydroxide (1 mL, 4 mmol) was slowly added at this temperature, then 30% hydrogen peroxide (0.46 mL, 4 mmol) was slowly added.
- the reaction mixture was heated to 50 ° C and stirred for 2 hours. After the reaction is completed, the reaction solution is poured into water, extracted with ethyl acetate, washed with aqueous sodium hydrogen sulfate solution and brine, dried and concentrated, and the obtained crude product is purified by column chromatography (silica gel column, eluent: acetic acid The title compound (yellow solid, 260 mg, 50%). (MS: [M+Na] 415.2)
- the third step 5-cyclopropyl-2-isopropoxyaniline
- the fourth step 4-bromo-5-cyclopropyl-2-isopropoxyaniline
- Step 5 4-(4-Amino-2-cyclopropyl-5-isopropoxyphenyl)-5,6-dihydropiperidine-1(2H)-tert-butyl carbonate
- Step 6 4-(4-Amino-5-isopropoxy-2-cyclopropylphenyl)piperidine-1-carbonate tert-butyl ester and 4-(4-amino-5-isopropoxy- 2-propylphenyl) piperidine-1-carbonate tert-butyl ester
- the third step 4-(5-cyclopropoxy-2-methyl-4-nitrophenyl)-3-fluoro-1-methylpiperidine
- the third step 4-(5-cyclopropoxy-2-methyl-4-nitrophenyl)-3,3-difluoropiperidine
- the third step 3-chloro-4-(5-cyclopropoxy-2-methyl-4-aminophenyl)-1-methylpiperidine
- the third step 5-chloro-4-(5-cyclopropoxy-2-methyl-4-nitro-phenyl)-1-methyl-1,2,3,6-tetrahydro-pyridine
- Second step 4-(5-cyclopropoxy-2-methyl-4-nitrophenyl)-5,5-dimethyl-5,6-dihydropyridine-1(2H)-carbonate Butyl ester
- the third step 4-(5-cyclopropoxy-2-methyl-4-nitrophenyl)-3,3-dimethyl-1,2,3,6-tetrahydropyridine
- the third step 4-(3-oxa-9-azabicyclo[3.3.1] ⁇ -7-yl)-2-cyclopropoxy-5-methylaniline
- Second step 4-(5-cyclopropoxy-2-methyl-4-nitrophenyl)-3,6-dihydro-2hydro-thiopyran-1,1 dioxide
- the third step 2-cyclopropoxy-4-(1,1-dioxo-4-tetrahydrothiopyranyl)-5-methylaniline
- N-(4-Fluorophenethyl)trifluoroacetic acid amine (2.66 g, 11.3 mmol), paraformaldehyde (0.56 g) and concentrated sulfuric acid/acetic acid (5.5 mL / 8.2 mL) were added to a 150 mL reaction flask. The reaction was stirred at room temperature for 20 hours under a nitrogen atmosphere. The reaction solution was poured into water (50 mL) and ethyl acetate was evaporated. The organic phase was combined, washed sequentially with saturated sodium bicarbonate, brine, dried and evaporated and evaporated. The title compound was obtained (1.98 g, 71%). (MS: [M+1] none)
- the third step N-trifluoroacetyl-7-fluoro-6-nitro-1,2,3,4-tetrahydroisoquinoline
- the fourth step 7-fluoro-6-nitro-1,2,3,4-tetrahydroisoquinoline
- N-methyl-7-fluoro-6-nitro-1,2,3,4-tetrahydroisoquinoline 150 mg, 0.72 mmol
- sodium tert-butoxide 85 mg, in a 25 mL nitrogen-protected reaction flask.
- 0.86 mmol 0.86 mmol
- N,N-dimethylformamide 5 mL
- the reaction was stirred at 0 ° C for 10 minutes, and a solution of cyclopropanol (54 mg, 0.93 mmol) in N,N-dimethylformamide (5 mL) was added, and the reaction was stirred at 0 ° C for 1 hour.
- Step 7 N-methyl-7-cyclopropoxy-1,2,3,4-tetrahydroisoquinolin-6-amine
- the third step 3-isopropylsulfonyl-1-methyl-4-aminopyrazole
- reaction mixture is poured into ice water, extracted with ethyl acetate, washed with saturated aqueous sodium hydrogen sulfate and brine, dried and concentrated, and the obtained crude product is purified by column chromatography (silica gel, eluent: acetic acid Ethyl ester/petroleum ether, gradient: EtOAc (EtOAc) (MS:[M+1]179.0)
- the third step 4-(isopropyl decyl)-2-methyl-5-nitrothiazole
- the third step 5-chloro-N 2 -(2-cyclopropoxy-5-methyl-4(1,4-dioxaspiro[4.5]dec-8-yl)phenyl)-N 4 - (3-(isopropylsulfonyl)-1-methyl-1hydro-pyrazol-4-yl)pyrimidine-2,4-diamine
- the final product 31-74 (Table 8) was prepared by the synthesis of the above final product 30.
- Example 177 5-Chloro-N 2 -(2-cyclopropoxy-5-methyl-4-((4-methylpiperazin-1-yl)methyl)phenyl)-N 4 - ( 3-(isopropylsulfonyl)-1-methyl-1hydro-pyrazol-4-yl)pyrimidine-2,4-diamine (final product 75)
- Example 178 5-Chloro-N 2 -(2-cyclopropoxy-5-methyl-4-(1-methylazetidin-3-yloxy)phenyl)-N 4 - (3-(isopropylsulfonyl-1-methyl-1hydro-pyrazol-4-yl)-pyrimidine-2,4-diamine (final product 76)
- the final product 78-113 was prepared using the above synthetic method of the final product 77 (Table 9).
- Example 216 5-Chloro-N 2 -[2-cyclopropoxy-4-(1-ethylpiperidin-4-yl)-5-methylphenyl]-N 4 -[1-methyl -3-(isopropylsulfonyl)-1hydro-pyrazol-4-yl]-pyrimidine-2,4-diamine (final product 114)
- the final product 115-122 was prepared using the above synthetic method of the final product 114 (Table 10).
- Example 225 5-Chloro-N 2 -[2-cyclopropoxy-4-(1-isopropylpiperidin-4-yl)-5-methylphenyl]-N 4 -[1- 3-(isopropylsulfonyl)-1hydro-pyrazol-4-yl]-pyrimidine-2,4-diamine (final product 123)
- the final product 124-132 was prepared using the above synthetic method of the final product 123 (Table 11).
- Example 235 2-(4-(4-(5-chloro-4-(3-(isopropylsulfonyl)-1-methyl-1hydro-pyrazole-4-amino)pyrimidine-2-amino) -5-cyclopropoxy-2-methylphenyl)piperidin-1-yl)ethanol (final product 133)
- Example 244 5-Chloro-N 2 -(2-isopropoxy-4-(1-(2-methoxyethyl)piperidin-4-yl)-5-methylphenyl)-N 4 -(3-(isopropylsulfonyl)-1-methyl-1hydro-pyrazole-4-)-pyrimidine-2,4-diamine (final product 142)
- Example 247 5-Chloro-N 2 -[2-cyclopropoxy-4-(1-(2-fluoroethyl)piperidin-4-yl)-5-methylphenyl]-N 4 - [1-Methyl-3-(isopropylsulfonyl)-1hydro-pyrazol-4-yl]-pyrimidine-2,4-diamine (final product 145)
- Example 248 5-Chloro-N 2 -(2-cyclopropoxy-4-(1-(2-(dimethylamino)ethyl)piperidin-4-yl)-5-methylphenyl) N 4 -(3-(isopropylsulfonyl)-1-methyl-1hydro-pyrazol-4-yl)-pyrimidine-2,4-diamine (final product 146)
- Example 249 2-(4-(4-(5-chloro-4-(3-(isopropylsulfonyl)-1-methyl-1hydro-pyrazole-4-amino)pyrimidine-2-amino) -5-cyclopropoxy-2-methylphenyl)piperidin-1-yl)-2-methyl-1-propanol (final product 147)
- Second step 2-(4-(4-(5-chloro-4-(3-(isopropylsulfonyl)-1-methyl-1hydro-pyrazole-4-amino)pyrimidine-2-amino) -5-cyclopropoxy-2-methylphenyl)piperidin-1-yl)-2-methyl-1-propanol
- the final product 148-154 (Table 13) was prepared by the synthesis of the above final product 147.
- Example 257 2-(4-(4-(5-Chloro-4-(3-isopropoxysulfonyl)-1-methyl-1hydro-pyrazol-4-ylamino)pyrimidine- 2-Aminoamino)-5-cyclopropoxy-2-methylphenyl)piperidin-1-yl)-N,N-dimethyl B Amide (final product 155)
- Example 258 5-Chloro-N 2 -(2-cyclopropoxy-4-(1-(oxetan-3-yl)piperidin-4-yl)-5-methylphenyl) -N 4 -(3-(isopropylsulfonyl)-1-methyl-1hydro-pyrazol-4-yl)pyrimidine-2,4-diamine (final product 156)
- Example 259 5-Chloro-N 2 -[2-cyclopropoxy-4-(1-cyclopropylpiperidin-4-yl)-5-methylphenyl]-N 4 -[3-iso Propylsulfonyl)-1hydro-pyrazole-1-methyl-1hydro-pyrazol-4-yl]pyrimidine-2,4-diamine (final product 157)
- Example 260 5-Chloro-N 2 -(2-cyclopropoxy-5-methyl-4-(1-(1-methyl-piperidin-4-yl)piperidin-4-yl)benzene -N 4 -(3-(isopropoxysulfonyl)-1-methyl-1hydro-pyrazol-4-yl)pyrimidine-2,4-diamine (final product 158)
- Example 261 4-(4-(5-Chloro-4-(3-(isopropylsulfonyl)-1-methyl-1hydro-pyrazol-4-ylamino)pyrimidin-2-amino)- 5-cyclopropoxy-2-methylphenyl)piperidine-1-carbaldehyde (final product 159)
- Example 262 1-Acetyl-4-(4-(5-chloro-4-(3-(isopropylsulfonyl)-1-methyl-1hydro-pyrazol-4-ylamino)pyrimidine-2 -amino)-5-cyclopropoxy-2-methylphenyl)piperidine (final product 160)
- Example 263 1-Trifluoroacetyl-4-(4-(5-chloro-4-(3-(isopropylsulfonyl)-1-methyl-1hydro-pyrazol-4-ylamino)pyrimidine 2-amino)-5-cyclopropoxy-2-methylphenyl)piperidine (final product 161)
- the synthesis of the final product 160 is carried out from 5-chloro-N 2 -(2-cyclopropoxy-4-piperidin-4-yl-5-methylphenyl)-N 4 -[1-methyl Reaction of -3-(isopropylsulfonyl)-1hydro-pyrazol-4-yl]-pyrimidine-2,4-diamine and trifluoroacetic anhydride afforded the title compound (m. (MS:[M+1]656.1)
- Example 264 1-Cyclopropylformyl-4-(4-(5-chloro-4-(3-(isopropylsulfonyl)-1-methyl-1hydro-pyrazol-4-ylamino)pyrimidine 2-amino)-5-cyclopropoxy-2-methylphenyl)piperidine (final product 162)
- Example 265 1-isobutyryl-4-(4-(5-chloro-4-(3-(isopropylsulfonyl)-1-methyl-1hydro-pyrazol-4-ylamino)pyrimidine- 2-Amino)-5-cyclopropoxy-2-methylphenyl)piperidine (final product 163)
- Example 266 1-pivaloyl-4-(4-(5-chloro-4-(3-(isopropylsulfonyl)-1-methyl-1hydro-pyrazol-4-ylamino)pyrimidine- 2-Amino)-5-cyclopropoxy-2-methylphenyl)piperidine (final product 164)
- Example 267 1-(2-Dimethylamino)acetyl-4-(4-(5-chloro-4-(3-(isopropylsulfonyl)-1-methyl-1 hydrogen-pyrazole-4 -amino)pyrimidin-2-amino)-5-cyclopropoxy-2-methylphenyl)piperidine (final product 165)
- Example 268 1-cyanoacetyl-4-(4-(5-chloro-4-(3-(isopropylsulfonyl)-1-methyl-1hydro-pyrazol-4-ylamino)pyrimidine- 2-amino)-5-cyclopropoxy-2-methylphenyl)piperidine (final product 166)
- Example 269 5-Chloro-N 2 -(2-cyclopropoxy-5-methyl-4-(1-methanesulfonylpiperidin-4-yl)-phenyl)-N 4 -(3- (isopropylsulfonyl)-1-methyl-1hydro-pyrazol-4-yl)pyrimidine-2,4-diamine (final product 167)
- the final product 168-173 (Table 14) was prepared by the synthesis of the final product 167.
- Example 276 4-(4-(5-Chloro-4-(3-(isopropylsulfonyl)-1-methyl-1hydro-pyrazol-4-amine)pyrimidin-2-amine)-5- Cyclopropoxy-2-methylphenyl)-N-ethyl-piperidine-1-carboxamide (final product 174)
- Example 277 5-Chloro-N 2 -(2-cyclopropoxy-4-(4-(dimethylamino)cyclohexyl)-5-methylphenyl)-N 4 -(3-(iso Butyryl)-1-methyl-1hydro-pyrazol-4-yl)pyrimidine-2,4-diamine (cis final product 175, trans final product 176)
- the final product 177-204 was prepared from the corresponding ketone and amine by reductive amination using a similar synthetic procedure as the final product 175 (reduction system was slightly different) (Table 15).
- Example 306 N-(4-(4-(5-chloro-4-(3-(isopropylsulfonyl)-1-methyl-1hydro-pyrazol-4-amine)pyrimidin-2-amine) -5-cyclopropoxy-2-methylphenyl)cyclohexyl)methanesulfonamide (final product 205)
- Example 309 5-Chloro-N 2 -[4-(5-chloro-1-methyl-1,2,3,6-tetrahydro-pyridin-4-yl)-2-cyclopropoxy-5 -methyl-phenyl]-N 4 -[1-methyl-3-(isopropylsulfonyl)-1hydro-pyrazol-4-yl]-pyrimidine-2,4-diamine (end product 208)
- Example 310 N 2 -[2-cyclopropoxy-4-(1-methylpiperidin-4-yl)-5-methylphenyl]-N 4 -[1-methyl-3-( Isopropylsulfonyl)-1hydro-pyrazol-4-yl]-5-(trifluoromethyl)pyrimidine-2,4-diamine (final product 209)
- Example 311 N 2 -[2-cyclopropoxy-4-(1-methylpiperidin-4-yl)-5-methylphenyl]-N 4 -[1-methyl-3-( Isopropylsulfonyl)-1hydro-pyrazol-4-yl]-5-(cyano)pyrimidine-2,4-diamine (final product 210)
- Example 312 5-Chloro-N 2 -[2-cyclopropoxy-4-(1-methylpiperidin-4-yl)-5-methylphenyl]-N 4 -[1-methyl 3-cyano-1 hydrogen-pyrazol-4-yl]-pyrimidine-2,4-diamine (final product 211)
- Example 313 Known compound 5-chloro-N 2 -[2-isopropoxy-4-(1-methylpiperidin-4-yl)-5-methylphenyl]-N 4 -[5 -methyl-1hydro-pyrazol-3-yl]-pyrimidine-2,4-diamine (final product 212)
- Example 320 Inhibitory activity of a compound of the invention against ALK kinase
- HTRF KinEASE TM -TK Assay kit (Cisbio, catalog number 62TK0PEC); Wildtype ALK kinase (produced by Sino-American Crown, batch number ALK_20110607); DTT (Gibco BRL, catalog number 15508-012); MgCl 2 (Sigma Aldrich, catalog number M-2670); ATP (Sigma Aldrich, catalog number A-7699); DMSO (AMRESCO, catalog number 0231); EDTA (AMRESCO, catalog number 0105); 96-well plate (compound) For dilution) (CITOTEST, catalog number Ref36020096D); OptiPlate TM -384 (White), PerkinElmer, catalog number P12-004)
- the compound (final concentration of DMSO was 1%) was mixed with the reaction substrate (final concentration of 1 ⁇ M), ATP (final concentration of 20 ⁇ M), and Wildtype ALK kinase (final concentration of 1 ng/ ⁇ l) in the final volume. It was a 10 ⁇ l reaction system (containing 5 mM MgCl 2 , 1X Kinase buffer, and 1 mM DTT). After shaking for 30 seconds, the reaction was carried out at 30 ° C for 35 minutes. After completion of the reaction, 5 ⁇ l of Sa-XL665 solution and 5 ⁇ l of TK Antibody-Eu (K) were added to each well, mixed uniformly, and left at 30 ° C for 60 minutes in the dark to terminate the reaction. Plates were read on a PerkinElmer EnVision plate reader (615 nM, 665 nM), the ratio of 665/615 was calculated, and the data was analyzed.
- Inhibition rate (%) [1-(R compound - R min ) / (R max - R min )] X 100
- HTRF KinEASE TM -TK Assay kit (Cisbio, catalog number 62TK0PEC); L1196M mutation Kinase (produced by Sino-US Crown, batch number ALKm_20110923); DTT (Gibco BRL, catalog number 15508-012); MgCl 2 (Sigma Aldrich, catalog number M-2670); ATP (Sigma Aldrich, catalog number A-7699) , Lot 051M7014V); DMSO (AMRESCO, catalog number 0231); EDTA (AMRESCO, catalog number 0105); 96-well plate (for compound dilution) (CITOTEST, catalog number Ref36020096D); OptiPlate TM- 384 (White), PerkinElmer, catalog number P12-004)
- Inhibition rate (%) [1-(R compound - R min ) / (R max - R min )] X 100
- Luminescent Cell Viability Assay Kit Promega, Cat. No. G7573; NCI-H2228 Cell Line (ATCC, Cat. No. CRL-5935); RPMI-1640 Medium (HyClone, Cat. No. SH30809.01B); Fetal Bovine Serum ( FBS) (Gibco, Cat. No. 10099-141); Trypsin (Gibco, Cat. No. 25200-072); PBS (HyClone, Cat. No. SH30256.01B); 96-well cell culture plate (Corning, Catalog No. 3610); DMSO (AMRESCO, Cat. No. 0231); 96-well plate (for compound dilution) (CITOTEST, Cat. No. Ref36020096D).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (21)
- 式I所示的化合物或其药用盐,其中,R1为烷基,卤代烷基或-O-R4,其中R4为氢,C1-8烷基,卤代C1-8烷基,C3-8环烷基,卤代C3-8环烷基,C1-8烷基-C3-8环烷基,C3-8环烷基-C1-8烷基,取代或未取代的杂环基,或取代或未取代的杂环基-C1-8烷基;R2为烷基,环烷基,杂环烷基或杂环烯基,它们可以任选地被1-3个独立地选自下组的取代基所取代:氧基,C1-8烷基,卤代C1-8烷基,C1-8烷氧基,卤代C1-8烷氧基,C3-8环烷基,卤代C3-8环烷基,C3-8环烷氧基,卤代C3-8环烷氧基,C1-8烷氧基-C1-8烷基,羟基-C1-8烷基,氨基-C1-8烷基,羧基-C1-8烷基,C1-8烷基-氨基-C1-8烷基,卤素,羟基,氰基,氰基-C1-8烷基,氨基,C1-8烷基-氨基,二(C1-8烷基)-氨基,C3-8环烷基-氨基,取代或未取代的芳香基,取代或未取代的杂芳香基,取代或未取代的杂环基,取代或未取代的杂环基-烷基,(CH2)nCONR5R6,-COR5,-SO2R5和-NR5SO2R6,其中n为0-8的整数,R5和R6彼此独立地为氢,烷基,卤代烷基,环烷基,卤代环烷基,氨基,C1-8烷基-氨基,二(C1-8烷基)-氨基,氰基-C1-8烷基,C1-8烷基-氨基-C1-8烷基或二(C1-8烷基)-氨基-C1-8烷基,其中所述取代基可选择地和它们所连接的碳原子一起形成环;R3为-SO2R7,-SO2NR7R8,-CN,-CONR7R8,或-COR7,其中R7和R8彼此独立地为氢,烷基或环烷基;X为化学键、O、S、CO、NR9、SO2或S(O),其中R9为氢,C1-8烷基,卤代C1-8烷基,C3-8环烷基,卤代C3-8环烷基C1-8烷基-CO或4-6元杂环基;Z1为N或C-R10,其中R10为氢,卤素,烷基,卤代烷基,环烷基,卤 代环烷基,烷氧基,卤代烷氧基或氰基;Z2为C-R11或N,其中R11为氢,C1-8烷基,卤代C1-8烷基,C3-8环烷基,卤代C3-8环烷基,C1-8烷氧基,卤代C1-8烷氧基,C3-8环烷氧基,卤代C3-8环烷氧基,卤素,氨基,C1-8烷基-氨基,二(C1-8烷基)-氨基或氰基,其中R11可选择地和R2以及和它们所连接的碳原子一起形成环,所述环可以任选地被1-3个独立地选自以下组的取代基所取代:氧基,C1-8烷基,卤代C1-8烷基,C1-8烷氧基,卤代C1-8烷氧基,C3-8环烷基,卤代C3-8环烷基,C3-8环烷氧基,卤代C3-8环烷氧基,C1-8烷氧基-C1-8烷基,羟基-C1-8烷基,氨基-C1-8烷基,羧基-C1-8烷基,C1-8烷基-氨基-C1-8烷基,卤素,羟基,氰基,氰基-C1-8烷基,氨基,C1-8烷基-氨基,二(C1-8烷基)-氨基,C3-8环烷基-氨基,取代或未取代的芳香基,取代或未取代的杂芳香基,取代或未取代的杂环基,取代或未取代的杂环基烷基,(CH2)nCONR12R13,-COR12,-SO2R12和-NR12SO2R13,其中n为0-8的整数,R12和R13彼此独立地为氢,烷基,卤代烷基,环烷基,卤代环烷基,氨基,C1-8烷基-氨基,二(C1-8烷基)-氨基,氰基-C1-8烷基,C1-8烷基-氨基-C1-8烷基或二(C1-8烷基)-氨基-C1-8烷基;Z3,Z4和Z5选自以下组:Z3为N,Z4为N-R14,Z5为CH或N;Z3为N,Z4为C-R14,Z5为N,O或S;Z3为O或S,Z4为N-R14,Z5为CH;Z3为O或S,Z4为C-R14,Z5为N;和Z3为C,Z4为N-R14,Z5为O或S;其中R14为氢,烷基,卤代烷基,C3-8环烷基,卤代C3-8环烷基或4-6元杂环基。
- 根据权利要求1所述的化合物或其药用盐,其中R1为C1-8烷基,C1-8卤代烷基或-O-R4,其中R4为氢,C1-8烷基,卤代C1-8烷基,C3-8环烷基,卤代C3-8环烷基,C1-8烷基-C3-8环烷基,C3-8环烷基-C1-8烷基,取代或未取代的4-7元杂环基或取代或未取代的4-7元杂环基-C1-8烷基;优选地,R4为氢,C1-8烷基,卤代C1-8烷基,C3-8环烷基,卤代C3-8环烷基,C1-8烷基-C3-8环烷基,C3-8环烷基-C1-8烷基,取代或未取代的包含1或2个选自N、O和S的杂原子的4-7元杂环基或取代或未取代的包含1或2个选自N、O和S的杂原子的4-7元杂环基-C1-8烷基;更优选地,R4为C1-5烷基,卤代C1-5烷基,C3-7环烷基,卤代C3-7环烷基或C3-7环烷基-甲基;最优选地,R4为甲基,乙基,正丙基,异丙基,环丙基,三氟甲基,环丁基或环丙基甲基。
- 根据权利要求1或2所述的化合物或其药用盐,其中R2为C1-8烷基,C3-8环烷基,4-7元杂环烷基或4-7元杂环烯基,它们可以任选地被1-3个独立地选自下组的取代基所取代:氧基,C1-8烷基,卤代C1-8烷基,C1-8烷氧基,卤代C1-8烷氧基,C3-8环烷基,卤代C3-8环烷基,C3-8环烷氧基,卤代C3-8环烷氧基,C1-8烷氧基-C1-8烷基,羟基-C1-8烷基,氨基-C1-8烷基,羧基-C1-8烷基,C1-8烷基-氨基-C1-8烷基,卤素,羟基,氰基,氰基-C1-8烷基,氨基,C1-8烷基-氨基,二(C1-8烷基)-氨基,C3-8环烷基-氨基,取代或未取代的芳香基,取代或未取代的杂芳香基,取代或未取代的4-7元杂环基,取代或未取代的4-7元杂环基-C1-8烷基,-(CH2)nCONR5R6,-COR5,-SO2R5和-NR5SO2R6,其中n为0-8的整数,R5和R6彼此独立地为氢,C1-8烷基,卤代C1-8烷基,C3-8环烷基,卤代C3-8环烷基,氨基,C1-8烷基-氨基,二(C1-8烷基)-氨基,氰基-C1-8烷基,C1-8烷基-氨基-C1-8烷基或二(C1-8烷基)-氨基-C1-8烷基,其中所述取代基可选择地和它们所连接的碳原子一起形成取代或未取代的环;优选地,R2为C1-8烷基,C3-8环烷基,包含1或2个选自N、O和S的杂原子的4-7元杂环烷基或包含1或2个选自N、O和S的杂原子的4-7元杂环烯基,它们可以任选地被1-3个独立地选自下组的取代基所取代:氧基,C1-8烷基,卤代C1-8烷基,C1-8烷氧基,卤代C1-8烷氧基,C3-8环烷基,卤代C3-8环烷基,C3-8环烷氧基,卤代C3-8环烷氧基,C1-8烷氧基-C1-8烷基,羟基-C1-8烷基,氨基-C1-8烷基,羧基-C1-8烷基,C1-8烷基-氨基-C1-8烷基,卤素,羟基,氰基,氰基-C1-8烷基,氨基,C1-8烷基-氨基,二(C1-8烷基)-氨基,C3-8环烷基-氨基,取代或未取代的芳香基,取代或未取代的杂芳香基,取代或未取代的4-7元杂环基,取代或未取代的4-7元杂环基-C1-8烷基,-(CH2)nCONR5R6,-COR5,-SO2R5和-NR5SO2R6,其中n为0-8的整数,R5和R6彼此独立地为氢,C1-8烷基,卤代C1-8烷基,C3-8环烷基,卤代C3-8环烷基,氨基,C1-8烷基-氨基,二(C1-8烷基)-氨基,或氰基-C1-8烷基,C1-8烷基-氨基-C1-8烷基或二(C1-8烷基)-氨基-C1-8烷基,其中所述取代基 可选择地和它们所连接的碳原子一起形成取代或未取代的环;更优选地,R2为C3-8环烷基,包含1或2个选自N、O和S的杂原子的4-7元杂环烷基或包含1或2个选自N、O和S的杂原子的4-7元杂环烯基,它们任选地被1-3个独立地选自下组的取代基所取代:C1-8烷基,卤代C1-8烷基,C1-8烷氧基,C3-8环烷基,C3-8环烷氧基,C1-8烷氧基-C1-8烷基,羟基-C1-8烷基,氨基-C1-8烷基,C1-8烷基-氨基-C1-8烷基,卤素,氰基,氰基-C1-8烷基,氨基,C1-8烷基-氨基,二(C1-8烷基)-氨基,C3-8环烷基-氨基,取代或未取代的4-7元杂环基,-CONR5R6,-COR5,-SO2R5和-NR5SO2R6,其中R5和R6彼此独立地为氢,C1-8烷基,卤代C1-8烷基,C3-8环烷基,氨基,C1-8烷基-氨基,二(C1-8烷基)-氨基,氰基-C1-8烷基,C1-8烷基-氨基-C1-8烷基或二(C1-8烷基)-氨基-C1-8烷基;最优选地,R2为环己烷,哌啶,吡咯烷,吖丁啶,四氢吡喃,吗啡啉或3-4烯哌啶,它们任选地被1-3个独立地选自下组的取代基所取代:甲基,乙基,正丙基,异丙基,正丁基,仲丁基,异丁基,叔丁基,环丙基,环丁基,噁丁环,甲氧基,甲氧甲基,甲氧乙基,氟,氯,氰基,氨基,环丙基氨基,(异丙基,甲基)-氨基,甲酰基,乙酰基,三氟乙酰基,环丙甲酰,-COR5,-SO2R5和-NR5SO2R6,其中R5和R6彼此独立地为氢,C1-5烷基,二甲基氨基,二甲基氨基甲基,乙基氨基或氰基甲基。
- 根据权利要求1至3中任一项所述的化合物或其药用盐,其中R3为-SO2R7,-SO2NR7R8,-CN,-CONR7R8,或-COR7,其中R7和R8彼此独立地为氢,C1-8烷基或C3-8环烷基;优选地,R3为-SO2R7,其中R7为氢,C1-8烷基或C3-8环烷基;更优选地,R3为-SO2R7,其中R7为异丙基,仲丁基或异丁基。
- 根据权利要求1至4中任一项所述的化合物或其药用盐,其中,X为化学键或CO。
- 根据权利要求1至5中任一项所述的化合物或其药用盐,其中,Z1为C-R10,其中R10为氢,卤素,C1-8烷基,卤代C1-8烷基,C3-8环烷基,卤代C3-8环烷基,C1-8烷氧基,卤代C1-8烷氧基或氰基;优选地,R10为卤素;更优选地,R10为氯。
- 根据权利要求1至6中任一项所述的化合物或其药用盐,其中,Z2为C-R11,其中R11为氢,C1-8烷基,卤素或氰基,其中R11可选择地和R2以及和它们所连接的碳原子一起形成环,所述环可以任选地被1-3个独立地选自下列的取代基所取代:氧基,C1-8烷基,卤代C1-8烷基,C1-8烷氧基,卤代C1-8烷氧基,C3-8环烷基,卤代C3-8环烷基,C3-8环烷氧基,卤代C3-8环烷氧基,C1-8烷氧基-C1-8烷基,羟基-C1-8烷基,氨基-C1-8烷基,羧基-C1-8烷基,C1-8烷基-氨基-C1-8烷基,卤素,羟基,氰基,氰基-C1-8烷基,氨基,C1-8烷基-氨基,二(C1-8烷基)氨基,C3-8环烷基-氨基,取代或未取代的芳香基,取代或未取代的杂芳香基,取代或未取代的杂环基,取代或未取代的杂环基-烷基,-(CH2)nCONR12R13,-COR12,-SO2R12和-NR12SO2R13,其中n为0-8的整数,R12和R13彼此独立地为氢,烷基,卤代烷基,环烷基,卤代环烷基,氨基,C1-8烷基-氨基,二(C1-8烷基)-氨基,氰基C1-8烷基,C1-8烷基-氨基-C1-8烷基或二(C1-8烷基)-氨基-C1-8烷基;优选地,R11和R2以及和它们所连接的碳原子一起形成环;更优选地,R11为氢,C1-8烷基,卤素或氰基;最优选地,R11为氢,甲基,氟,氯或氰基。
- 根据权利要求1至7中任一项所述的化合物或其药用盐,其中,Z3,Z4和Z5选自以下组:Z3为N,Z4为N-R14,Z5为CH或N,Z3为N,Z4为C-R14,Z5为N,O或S,Z3为O或S,Z4为N-R14,Z5为CH,Z3为O或S,Z4为C-R14,Z5为N,和Z3为C,Z4为N-R14,Z5为O或S,其中R14为氢,C1-8烷基,C3-8环烷基,卤代C3-8环烷基,包含1或2个选自N、O和S的杂原子的4-6元杂环基或包含1或2个选自N、O和S的杂原子的卤代4-6元杂环基。
- 根据权利要求1至8中任一项所述的化合物或其药用盐,其中,Z3为N,Z4为N-R14,Z5为CH,其中R14为氢,C1-8烷基,C3-8环烷基,卤代C3-8 环烷基,包含1或2个选自N、O和S的杂原子的4-6元杂环基或包含1或2个选自N、O和S的杂原子的卤代4-6元杂环基;优选地,R14为C1-8烷基或C3-8环烷基;更优选地,R14为甲基或环丙基。
- 根据权利要求1至9中任一项所述的化合物或其药用盐,其中,Z3为N,Z4为C-R14,Z5为S,其中R14为C1-8烷基或C3-8环烷基;优选地,R14为甲基或环丙基。
- 一种包含权利要求1至13中任一项所述的化合物或其药用盐的药物组合物;优选地,该药物组合物包含药学上可接受的载体或赋形剂。
- 根据权利要求15所述的药物组合物,其中所述药物组合物为片剂、胶囊剂、丸剂、颗粒剂、散剂、栓剂、注射剂、溶液剂、混悬剂、膏剂、贴 剂、洗剂、滴剂、擦剂或喷雾剂。
- 权利要求1至13中任一项所述的化合物或其药用盐和/或权利要求15至16中任一项所述的药物组合物在制备抗肿瘤的药物中的应用。
- 根据权利要求17所述的应用,其中,所述抗肿瘤药物应用于以下病症:黑色素瘤,神经母细胞瘤,胶质母细胞瘤,横纹肌肉瘤,星形细胞瘤,尤因氏肉瘤,视网膜母细胞瘤,间变性大细胞淋巴瘤,炎性肌纤维母细胞瘤,弥漫性大B细胞淋巴瘤,非小细胞肺癌,肾髓质癌,肾细胞癌,乳房癌,结肠癌,卵巢浆液性癌和食管的鳞状细胞癌。
- 一种治疗主体中肿瘤的方法,包括向所述主体给与治疗有效量的权利要求1至13中任一项所述的化合物或其药用盐和/或权利要求15至16中任一项所述的药物组合物。
- 根据权利要求19所述的方法,其中所述主体是哺乳动物;优选地,所述主体是人。
- 根据权利要求19或20所述的方法,其中给药方式包括口腔、粘膜、舌下、眼部、局部、肠道外、直肠、脑池、阴道、腹膜、膀胱、鼻部给药。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15800668.4A EP3150592B1 (en) | 2014-05-30 | 2015-05-29 | Alk kinase inhibitor, and preparation method and use thereof |
AU2015266453A AU2015266453C1 (en) | 2014-05-30 | 2015-05-29 | Alk kinase inhibitor, and preparation method and use thereof |
BR112016028017-2A BR112016028017B1 (pt) | 2014-05-30 | 2015-05-29 | Compostos inibidores de quinase alk, composições farmacêuticas compreendendo os mesmos, seus métodos de preparação e seus usos |
JP2016571080A JP6339241B2 (ja) | 2014-05-30 | 2015-05-29 | Alkキナーゼ阻害剤並びにその調製方法及び使用 |
US15/314,876 US10023593B2 (en) | 2014-05-30 | 2015-05-29 | ALK kinase inhibitor, and preparation method and uses thereof |
KR1020167036475A KR101881886B1 (ko) | 2014-05-30 | 2015-05-29 | Alk 키나제 억제제, 이의 제조방법 및 이의 용도 |
ZA2017/00021A ZA201700021B (en) | 2014-05-30 | 2017-01-03 | Alk kinase inhibitor, and preparation method and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410238263.6 | 2014-05-30 | ||
CN201410238263 | 2014-05-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015180685A1 true WO2015180685A1 (zh) | 2015-12-03 |
Family
ID=54698131
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2015/080273 WO2015180685A1 (zh) | 2014-05-30 | 2015-05-29 | Alk激酶抑制剂及其制备方法和应用 |
Country Status (9)
Country | Link |
---|---|
US (1) | US10023593B2 (zh) |
EP (1) | EP3150592B1 (zh) |
JP (1) | JP6339241B2 (zh) |
KR (1) | KR101881886B1 (zh) |
CN (1) | CN105294654B (zh) |
AU (1) | AU2015266453C1 (zh) |
HK (1) | HK1219952A1 (zh) |
WO (1) | WO2015180685A1 (zh) |
ZA (1) | ZA201700021B (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106866684A (zh) * | 2015-12-10 | 2017-06-20 | 杭州雷索药业有限公司 | 用于治疗肿瘤的大环衍生物 |
AU2015385326B2 (en) * | 2015-03-04 | 2019-04-18 | Novartis Ag | Chemical process for preparing pyrimidine derivatives and intermediates thereof |
CN110563656A (zh) * | 2018-06-06 | 2019-12-13 | 四川大学 | 嘧啶类小分子化合物及在制备抗分枝杆菌药物中的用途 |
US10710993B2 (en) * | 2016-06-27 | 2020-07-14 | Hangzhou REX Pharmaceutical Co., LTD. | Benzofuran pyrazole amine kinase inhibitor |
WO2020188015A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106083595A (zh) * | 2016-06-08 | 2016-11-09 | 常州安迪沃克医药科技有限公司 | 抗癌药物色瑞替尼中间体2‑氯(溴)‑4‑氟‑5‑硝基甲苯的合成方法 |
CN111362922A (zh) * | 2018-12-26 | 2020-07-03 | 上海喆邺生物科技有限公司 | 2,4-二氨基嘧啶衍生物及其用途 |
EP3990445A4 (en) * | 2019-06-25 | 2023-07-05 | InventisBio Co., Ltd. | HETEROCYCLIC COMPOUNDS, METHODS FOR THEIR PREPARATION AND THEIR METHODS OF USE |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009032669A2 (en) * | 2007-09-06 | 2009-03-12 | Polyone Corporation | Soft, shock-damping thermoplastic elastomers |
CN101535276A (zh) * | 2006-10-23 | 2009-09-16 | 赛福伦公司 | 作为ALK和c-MET抑制剂的2,4-二氨基嘧啶稠合双环衍生物 |
CN102105150A (zh) * | 2008-05-21 | 2011-06-22 | 阿里亚德医药股份有限公司 | 用作激酶抑制剂的磷衍生物 |
CN102112467A (zh) * | 2008-06-25 | 2011-06-29 | Irm责任有限公司 | 作为激酶抑制剂的嘧啶衍生物 |
CN102203083A (zh) * | 2008-06-25 | 2011-09-28 | Irm责任有限公司 | 作为激酶抑制剂的嘧啶衍生物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2007754A1 (en) * | 2006-04-10 | 2008-12-31 | Boehringer Ingelheim International GmbH | 2, 4-diaminopyrimidine derivatives and their use for the treatment of cancer |
KR101174201B1 (ko) * | 2007-08-28 | 2012-08-16 | 아이알엠 엘엘씨 | 키나제 억제제로서의 2-비페닐아미노-4-아미노피리미딘 유도체 |
CN102317268A (zh) * | 2008-06-25 | 2012-01-11 | Irm责任有限公司 | 作为激酶抑制剂的2-联苯基氨基-4-氨基嘧啶衍生物 |
WO2011120026A1 (en) * | 2010-03-26 | 2011-09-29 | Glaxo Group Limited | Pyrazolyl-pyrimidines as kinase inhibitors |
CN104672214B (zh) * | 2013-12-03 | 2019-04-12 | 上海翰森生物医药科技有限公司 | 具有alk抑制活性的化合物及其制备与用途 |
-
2015
- 2015-05-29 US US15/314,876 patent/US10023593B2/en active Active
- 2015-05-29 CN CN201510289037.5A patent/CN105294654B/zh active Active
- 2015-05-29 WO PCT/CN2015/080273 patent/WO2015180685A1/zh active Application Filing
- 2015-05-29 KR KR1020167036475A patent/KR101881886B1/ko active IP Right Grant
- 2015-05-29 JP JP2016571080A patent/JP6339241B2/ja active Active
- 2015-05-29 AU AU2015266453A patent/AU2015266453C1/en active Active
- 2015-05-29 EP EP15800668.4A patent/EP3150592B1/en active Active
-
2016
- 2016-07-11 HK HK16108050.2A patent/HK1219952A1/zh unknown
-
2017
- 2017-01-03 ZA ZA2017/00021A patent/ZA201700021B/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101535276A (zh) * | 2006-10-23 | 2009-09-16 | 赛福伦公司 | 作为ALK和c-MET抑制剂的2,4-二氨基嘧啶稠合双环衍生物 |
WO2009032669A2 (en) * | 2007-09-06 | 2009-03-12 | Polyone Corporation | Soft, shock-damping thermoplastic elastomers |
CN102105150A (zh) * | 2008-05-21 | 2011-06-22 | 阿里亚德医药股份有限公司 | 用作激酶抑制剂的磷衍生物 |
CN102112467A (zh) * | 2008-06-25 | 2011-06-29 | Irm责任有限公司 | 作为激酶抑制剂的嘧啶衍生物 |
CN102203083A (zh) * | 2008-06-25 | 2011-09-28 | Irm责任有限公司 | 作为激酶抑制剂的嘧啶衍生物 |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2015385326B2 (en) * | 2015-03-04 | 2019-04-18 | Novartis Ag | Chemical process for preparing pyrimidine derivatives and intermediates thereof |
AU2019202552B2 (en) * | 2015-03-04 | 2020-10-29 | Novartis Ag | Chemical process for preparing pyrimidine derivatives and intermediates thereof |
CN106866684A (zh) * | 2015-12-10 | 2017-06-20 | 杭州雷索药业有限公司 | 用于治疗肿瘤的大环衍生物 |
US10710993B2 (en) * | 2016-06-27 | 2020-07-14 | Hangzhou REX Pharmaceutical Co., LTD. | Benzofuran pyrazole amine kinase inhibitor |
CN110563656A (zh) * | 2018-06-06 | 2019-12-13 | 四川大学 | 嘧啶类小分子化合物及在制备抗分枝杆菌药物中的用途 |
WO2020188015A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Also Published As
Publication number | Publication date |
---|---|
CN105294654A (zh) | 2016-02-03 |
ZA201700021B (en) | 2018-12-19 |
KR101881886B1 (ko) | 2018-07-25 |
US10023593B2 (en) | 2018-07-17 |
US20170247392A1 (en) | 2017-08-31 |
HK1219952A1 (zh) | 2017-04-21 |
EP3150592A4 (en) | 2018-01-24 |
EP3150592A1 (en) | 2017-04-05 |
CN105294654B (zh) | 2018-01-09 |
BR112016028017A2 (pt) | 2023-01-10 |
EP3150592B1 (en) | 2023-08-30 |
AU2015266453A1 (en) | 2017-01-05 |
JP2017516825A (ja) | 2017-06-22 |
AU2015266453C1 (en) | 2018-09-13 |
AU2015266453B2 (en) | 2018-04-12 |
KR20170007483A (ko) | 2017-01-18 |
JP6339241B2 (ja) | 2018-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015180685A1 (zh) | Alk激酶抑制剂及其制备方法和应用 | |
TWI551595B (zh) | 2,4-disubstituted benzene-1,5-diamine derivatives and their use, Its preparation of pharmaceutical compositions and pharmaceutical compositions | |
CN105246884B (zh) | 用作激酶抑制剂的脲衍生物 | |
WO2020156243A1 (zh) | Shp2抑制剂及其应用 | |
JP6411342B2 (ja) | アミド化合物 | |
TWI739783B (zh) | 作為nik抑制劑的新穎的經取代氰基吲哚啉衍生物 | |
WO2015158310A1 (zh) | 一种酪氨酸激酶抑制剂及其用途 | |
WO2012053606A1 (ja) | アリールアミノヘテロ環カルボキサミド化合物 | |
JP2008531679A (ja) | オキシトシンアンタゴニストとしての1,2,4−トリアゾール誘導体とその使用 | |
WO2010058846A1 (ja) | 4,6-ジアミノニコチンアミド化合物 | |
WO2016169421A1 (zh) | 咪唑并异吲哚类衍生物、其制备方法及其在医药上的应用 | |
TW200930703A (en) | Quinolone derivative | |
JP2022513959A (ja) | 大環状化合物及び疾患の処置におけるそれらの使用 | |
WO2016169504A1 (zh) | 稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用 | |
JPWO2016039408A1 (ja) | 複素環化合物 | |
TWI778933B (zh) | 醫藥及醫藥品 | |
JP2021526123A (ja) | オートタキシン阻害剤とその使用 | |
WO2023059581A1 (en) | Heterobifunctional compounds and their use in treating disease | |
JP2024505732A (ja) | ピリドピリミジノン系誘導体及びその製造方法と使用 | |
JP7043483B2 (ja) | 二環式プロリン化合物 | |
CN102781914A (zh) | 吲哚衍生物 | |
TW201712011A (zh) | 作為bet家族溴結構域抑制劑之新穎吡啶吡酮 | |
WO2022222911A1 (zh) | 嘧啶酮化合物及其用途 | |
WO2021115495A1 (zh) | 一种小分子含硫杂环化合物 | |
WO2013107333A1 (zh) | 哌嗪基嘧啶类衍生物及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15800668 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016571080 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112016028017 Country of ref document: BR |
|
REEP | Request for entry into the european phase |
Ref document number: 2015800668 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015800668 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20167036475 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2015266453 Country of ref document: AU Date of ref document: 20150529 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15314876 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 112016028017 Country of ref document: BR Kind code of ref document: A2 Effective date: 20161129 |
|
ENPC | Correction to former announcement of entry into national phase, pct application did not enter into the national phase |
Ref document number: 112016028017 Country of ref document: BR Kind code of ref document: A2 Free format text: ANULADA A PUBLICACAO CODIGO 1.3 NA RPI NO 2433 DE 22/08/2017 POR TER SIDO INDEVIDA. |
|
ENPW | Started to enter national phase and was withdrawn or failed for other reasons |
Ref document number: 112016028017 Country of ref document: BR Kind code of ref document: A2 Free format text: PEDIDO RETIRADO EM RELACAO AO BRASIL POR NAO ATENDER AO ART. 6O DA RESOLUCAO INPI 77/2013 (NAO APRESENTA QUADRO REIVINDICATORIO TRADUZIDO NA PETICAO INICIAL). |
|
ENP | Entry into the national phase |
Ref document number: 112016028017 Country of ref document: BR Kind code of ref document: A2 Effective date: 20161129 |